Arp2/3 complex-driven spatial patterning of the BCR enhances immune synapse formation, BCR signaling and cell activation

Madison Bolger-Munro[1,2], **Kate Choi**[1,2], **Joshua M Scurll**[3], **Libin Abraham**[1,2,3], **Rhys Chappell**[3], **Duke Sheen**[1,2], **May Dang-Lawson**[1,2], **Xufeng Wu**[4], **John J Priatel**[5,6], **Daniel Coombs**[3], **John A Hammer**[4], **Michael R Gold**[1,2]

*For correspondence:
mgold@mail.ubc.ca (MRG);
mbolgerm@mail.ubc.ca (MB-M)

[1]Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada; [2]Life Sciences Institute and I3 Research Group, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada; [3]Department of Mathematics and Institute of Applied Mathematics, University of British Columbia, Vancouver, British Columbia, V6T 1Z2, Canada; [4]Cell Biology and Physiology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; [5]Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V5Z 4H4, Canada; [6]BC Children's Hospital Research Institute, Vancouver, British Columbia, V5Z 4H4, Canada

Abstract   When B cells encounter antigens on the surface of an antigen-presenting cell (APC), B cell receptors (BCRs) are gathered into microclusters that recruit signaling enzymes. These microclusters then move centripetally and coalesce into the central supramolecular activation cluster of an immune synapse. The mechanisms controlling BCR organization during immune synapse formation, and how this impacts BCR signaling, are not fully understood. We show that this coalescence of BCR microclusters depends on the actin-related protein 2/3 (Arp2/3) complex, which nucleates branched actin networks. Moreover, in murine B cells this dynamic spatial reorganization of BCR microclusters amplifies proximal BCR signaling reactions and enhances the ability of membrane-associated antigens to induce transcriptional responses and proliferation. Our finding that Arp2/3 complex activity is important for B cell responses to spatially-restricted membrane-bound antigens, but not for soluble antigens, highlights a critical role for Arp2/3 complex-dependent actin remodelling in B cell responses to APC-bound antigens.

Introduction

The binding of membrane-bound ligands to their receptors can initiate multiscale spatial reorganization of receptors and their signal transduction machinery. This presumably optimizes receptor signaling and is often driven by remodeling of the cortical cytoskeleton. The formation of an immune synapse between a lymphocyte and an antigen-presenting cell (APC) is an excellent model for studying the dynamic changes in receptor and cytoskeleton organization that occur during cell-cell interactions and how they impact cellular activation (*Dustin and Groves, 2012*; *Harwood and Batista, 2010*, *2011*; *Song et al., 2014*). B lymphocytes play a critical role in health and disease

by producing antibodies and cytokines. Although B cells can be activated by the binding of soluble antigens (Ags) to the B cell receptor (BCR), APCs that capture and concentrate Ags are potent activators of B cells (*Batista and Harwood, 2009*).

The immune synapse is a transient and highly dynamic structure that is characterized by a rapidly evolving reorganization of plasma membrane components and signaling proteins. When B cells encounter Ag on the surface of an APC, BCRs undergo rapid actin-dependent spatial reorganization that amplifies BCR signaling (*Harwood and Batista, 2010*) and reduces the amount of Ag required for B cell activation (*Batista et al., 2001*; *Depoil et al., 2008*; *Weber et al., 2008*). Initial BCR signaling induces localized actin severing and transiently uncouples the cortical cytoskeleton from the plasma membrane (*Freeman et al., 2011*; *Gupta et al., 2006*; *Treanor et al., 2011*). These changes allow for increased mobility of BCRs within the plasma membrane and enables the formation of BCR microclusters that are initially distributed throughout the B cell-APC contact site (*Batista et al., 2001*; *Depoil et al., 2008*). Because BCR signaling output depends on BCR-BCR interactions, microcluster formation amplifies BCR signaling. BCR clustering leads to phosphorylation of the CD79a/b (Ig-α/β) signaling subunit of the BCR (*Abraham et al., 2016*; *Dal Porto et al., 2004*). This allows recruitment of the Syk tyrosine kinase to the BCR, which nucleates formation of a 'microsignalosome', a microcluster-based signaling complex that includes the Btk tyrosine kinase, phospholipase Cγ2 (PLCγ2), and phosphoinositide 3-kinase (PI3K) (*Treanor et al., 2009*; *Weber et al., 2008*). BCR signaling stimulates actin polymerization at the periphery of the B cell-APC contact site (*Fleire, 2006*), which exerts outward force on the plasma membrane to generate membrane protrusions (*Mogilner and Oster, 1996*). This allows the B cell to scan the APC surface for additional Ag, resulting in further BCR microcluster formation and enhancement of BCR signaling (*Fleire, 2006*; *Weber et al., 2008*).

Subsequent retraction of the B cell membrane is accompanied by the centripetal movement of BCR-Ag microclusters, which coalesce to form the characteristic central supramolecular activation complex (cSMAC) of an immune synapse (*Fleire, 2006*). BCR-mediated extraction of Ag from the APC membrane, which allows B cells to present Ags and elicit T cell help, occurs at the cSMAC in naive B cells (*Nowosad et al., 2016*; *Yuseff et al., 2013*). In T cells, centripetal (i.e. retrograde) actin flow is a driving force for T cell receptor (TCR) microcluster centralization and cSMAC formation (*Babich et al., 2012*; *Hammer and Burkhardt, 2013*; *Yi et al., 2012*). As new actin is polymerized at the cell periphery, the elastic resistance of the plasma membrane causes the peripheral actin network to flow towards the center of the synapse (*Ponti et al., 2004*). Actin dynamics are required for cSMAC formation in B cells (*Liu et al., 2012*; *Treanor et al., 2011*) but a role for actin retrograde flow has not been established.

Although the actin-dependent formation, movement, and spatial organization of BCR micoclusters are critical for APC-induced B cell activation, the molecular mechanisms that orchestrate this process are not fully understood. Actin organization and dynamics are controlled by a large network of actin-regulatory proteins (*Bezanilla et al., 2015*; *Chhabra and Higgs, 2007*; *Michelot and Drubin, 2011*; *Tolar, 2017*). There are two main modes of actin polymerization (*Pollard, 2007*). Formin-mediated linear actin polymerization, which is controlled by the RhoA GTPase, generates thin membrane protrusions such as filopodia (*Mattila and Lappalainen, 2008*). Alternatively, branched actin polymerization is mediated by the 7-subunit actin-related protein (Arp) 2/3 complex, which binds to existing actin filaments and nucleates new filaments that grow at a 70° angle from the mother filament (*Goley and Welch, 2006*). Receptor-induced activation of the Cdc42 and Rac GTPases causes conformational changes in nucleation-promoting factors (NPFs) belonging to the Wiskott-Aldrich Syndrome protein (WASp) family, which allows them to activate the Arp2/3 complex (*Rotty et al., 2013*). The Arp2/3 complex nucleates the branched actin networks that underlie the formation of sheet-like membrane protrusions such as lamellipodia (*Pollard and Borisy, 2003*). The peripheral actin network at the T cell immune synapse resembles that of the lamellipodia of migrating cells (*Dustin, 2007*; *Dustin and Cooper, 2000*).

A key role for the Arp2/3 complex in T and B cells is suggested by the dysregulated lymphocyte

function in patients with Wiskott-Aldrich Syndrome (WAS). WAS is caused by mutations in either WASp or WASp-interacting protein (WIP) (*Candotti, 2018*) and is characterized by increased suscepti-bility to autoimmune disease, recurring infections, and predisposition to lymphomas and leukemias. In B cells, the WASp and N-WASp NPFs, as well as WIP, regulate actin dynamics and BCR signaling at the immune synapse (*Keppler et al., 2015*; *Liu et al., 2013*, *2011*; *Westerberg et al., 2010*). Although WASp and N-Wasp act upstream of the Arp2/3 complex, the role of Arp2/3 complex-dependent actin dynamics in B cell immune synapse formation and function has not been investigated.

B cell immune synapse formation was first demonstrated in the context of B cell-APC interactions (*Batista et al., 2001*). However, most subsequent studies have employed antigens that are attached to artificial planar lipid bilayers or to the cytoplasmic face of plasma membrane sheets in order to facilitate imaging of the contact site. We have developed systems for imaging APC-induced B cell immune synapse formation in real time (*Wang et al., 2018*) and now use this approach to investigate the role of Arp2/3 complex-dependent actin dynamics in B cell immune synapse formation and function. Here, we show that B cells interacting with live, intact APCs form BCR-Ag microclusters within dynamic actin-rich membrane protrusions that are dependent on the Arp2/3 complex. The coalescence of BCR-Ag microclusters into a cSMAC is also dependent on the dynamic branched actin networks that are nucleated by the Arp2/3 complex. Importantly, we show that Arp2/3 complex activity amplifies BCR signaling and is required for maximal B cell activation and proliferation.

Results

B cells generate dynamic actin-rich protrusions to scan for Ags on APCs

To visualize how B cells scan the surface of APCs to search for Ag, we generated APCs expressing a fluorescently-tagged, transmembrane form of hen egg lysozyme (mHEL-HaloTag) and then imaged the B cell-APC contact site in real time (*Figure 1*A). When A20 murine B-lymphoma cells expressing the HEL-specific D1.3 transgenic BCR (A20 D1.3 B cells) were added to the APCs, they rapidly formed BCR-Ag microclusters throughout the contact site. Microclusters that formed at the periphery moved centripetally. Closer to the center of the contact site, microclusters coalesced with each other such that a cSMAC developed within ~10 min (*Figure 1*B). Although some BCR-Ag microclusters formed quite far from the center of the contact site (*Figure 1*B [yellow arrowheads]), nearly all of the microclusters coalesced into the cSMAC after 10 min (*Figure 1*B, *Video 1*).

Membrane protrusions are generally driven by actin polymerization. To image how B cells probe the surface of APCs, we expressed the F-actin-binding protein F-Tractin-GFP in A20 D1.3 B cells and imaged their interaction with mHEL-HaloTag-expressing APCs using instant structured illumination microscopy (ISIM) (*York et al., 2013*) to obtain high spatiotemporal resolution. We found that B cells continually extended and retracted short-lived actin-rich protrusions across the surface of the APC (*Figure 1*C [colored arrowheads], *Figure 1*D, *Video 2*), resulting in an asymmetrical cell shape. This dynamic searching mechanism allowed A20 D1.3 B cells to scan a total area of ~100 µm^2 on the surface of the APC over 4 min of contact and gather Ag into microclusters (*Figure 1*D). BCR-Ag microclusters formed within actin-rich regions, including newly formed protrusions (*Figure 1*C, *Video 2*). These microclusters moved towards the center of the synapse along with the actin structures in which they were embedded, especially as membrane protrusions were retracted (*Figure 1*E, *Video 2*). As determined from the kymographs in *Figure 1*E, the velocities at which the peripheral F-actin structures and BCR-Ag microclusters moved towards the center of the synapse were similar, suggesting that actin dynamics drive the initial centripetal movement of these microclusters. At the same time, F-actin was cleared from the center of the contact site and BCR microclusters within this region coalesced with each other until a cSMAC was formed.

In contrast to their behavior on APCs, B cells exhibited largely radial spreading when they contacted immobilized anti-IgG antibodies (an Ag surrogate) on a rigid glass coverslip (*Figure 1*F, *Video 3*). The cells underwent continual outward spreading, reaching a contact area of ~150 µm^2 after 10 min (*Figure 1*G; see also *Figure 3*C,D). B cells spreading on immobilized anti-Ig formed

139 multiple large lamellipodia, some of which persisted for up to 10 min (for example, *Figure 1*F [blue
140 arrowheads]). They also formed short dynamic filopodia, many of which were retracted or engulfed
141 by newly formed lamellipodia.

The Arp2/3 complex is required for centralization of BCR-Ag microclusters

The Arp2/3 complex nucleates branched actin polymerization, which drives the formation of lamel-
lipodial protrusions, resembling those that were observed in B cells spreading on APCs (*Figure 1*C).
Because peripheral actin polymerization is associated with actin retrograde flow, we asked whether
Arp2/3 complex activity is required for the centralization of BCR-Ag microclusters. To address this
question, we used two complementary and well-characterized approaches to ablate the function of
the Arp2/3 complex in B cells. First, we used siRNA to deplete Arp3 expression. Depletion of Arp3
was accompanied by reduced expression of Arp2 and p34, suggesting destabilization of the Arp2/3
complex (*Figure 2-Figure Supplement 1*), as observed previously (*Nicholson-Dykstra and Higgs,*
2008; *Zhang et al., 2017*). Second, we inhibited Arp2/3 complex activity using a pharmacological
inhibitor, CK-666 (*Hetrick et al., 2013*). CK-666 locks the Arp2/3 complex in an open conformation,
which prevents it from binding to existing actin filaments and nucleating the formation of new actin
filaments. B cells treated with CK-666 did not exhibit increased cell death compared to controls
(*Figure 2-Figure Supplement 2*A,B). Although the COS-7 APCs would also be exposed to CK-666 in
these experiments, the CK-666 concentration that we used did not alter their F-actin organization
or dynamics over a 30-min timescale (*Figure 2-Figure Supplement 3*).
We found that inhibiting or depleting the Arp2/3 complex greatly reduced the coalescence of BCR-
Ag microclusters into a cSMAC (*Figure 2*A,B), even though there was no change in the total amount
of Ag that was gathered into microclusters (*Figure 2-Figure Supplement 4*A,B) or the number of
BCR-Ag microclusters that formed (*Figure 2-Figure Supplement 4*C,D). In A20 D1.3 B cells that were
transfected with control siRNA (*Figure 2*A, *Video 4*) or treated with CK-689 (*Figure 2*B, *Video 6*), an
inactive analog of CK-666, BCR-Ag microclusters exhibited obvious centripetal movement. By 10
min after contacting the APCs, ~60% of the B cells had gathered >90% of the Ag fluorescence
into one or two large clusters at the center of the synapse, which we define as having formed a
cSMAC (*Figure 2*A,B). By contrast, many of the BCR-Ag microclusters in the Arp3 siRNA-expressing
cells (*Figure 2*A, *Video 5*) and the CK-666-treated cells (*Figure 2*B, *Video 7*) did not exhibit persistent
centripetal motion and only ~15% of the cells in which the Arp2/3 complex was inhibited or depleted
formed a cSMAC by 10 min (*Figure 2*A,B). Even after 30 min, very few CK-666-treated cells formed a
cSMAC (data not shown).
The extent of BCR-Ag microcluster coalescence and cSMAC formation was further analyzed
by quantifying the distance of each microcluster on an individual B cell from the center of mass
of the Ag fluorescence (i.e. the center of the immune synapse). For each B cell, the average
microcluster distance was calculated for each frame in the video and this value was normalized
to the maximum average distance for that cell (*Figure 2-Figure Supplement 4*E,F). In A20 D1.3 B
cells that were transfected with control siRNA or treated with CK-689, the normalized average
distance from the center decreased over time, indicating that microclusters moved towards the
center of the immune synapse. This can be seen in kymographs depicting microclusters moving
centripetally from the cell periphery and merging with other microclusters at the center of the
immune synapse in *Figure 2-Figure Supplement 4*G,H. However, in Arp3 siRNA-transfected and
CK-666-treated A20 D1.3 B cells, the average distance of BCR microclusters from the center of the
synapse remained relatively unchanged over the entire 14-minute imaging period. This is reflected
in the kymoraphs in *Figure 2-Figure Supplement 4*G,H. To assess cSMAC formation, the distribution
of Ag fluorescence into clusters over time was quantified. Cumulative frequency distribution curves
showed that the 50th percentile (cumulative frequency = 0.5) for the number of clusters per cell
required to contain 90% of the Ag fluorescence after 10 min of B cell-APC contact was ~1 for the
control siRNA-transfected A20 D1.3 B cells and CK-689-treated cells versus 4 for the Arp3 siRNA-
transfected cells and CK-666-treated cells (*Figure 2-Figure Supplement 4*I,J). For example, after 10

Figure 1. B cells generate dynamic actin-based probing protrusions in response to APC-bound Ags. (A) Schematic of the B cell-APC system. COS-7 cells expressing mHEL-HaloTag Ag act as APCs for B cells expressing HEL-specific BCRs. (B) A20 D1.3 B cells were added to the COS-7 cells expressing mHEL-HaloTag and the B cell-APC contact site was imaged every 12 s for 14 min using spinning disk microscopy. Images from *Video 1* are shown. Yellow arrowheads indicate BCR-Ag microclusters that formed far from the center of the contact site. The data are representative of >40 cells from 9 independent experiments. Times are shown in minutes:seconds. *Figure 1 continued on next page.*

Figure 1 continued. (C) A20 D1.3 B cells expressing F-Tractin-GFP (green) were added to COS-7 APCs expressing mHEL-HaloTag (red) and the B cell-APC contact site was imaged every 6.6 s for 4 min using ISIM. Images from *Video 2* are shown. The different colored arrowheads in the upper panels (actin channel) represent membrane protrusions that were extended or retracted. The yellow circles in the lower panels indicate BCR-Ag microclusters (red) that were formed on new actin protrusions. (D) For each frame of *Video 2*, the cell edge, as defined by F-actin, was overlaid as a temporally-coded time series (left). The total area searched by the B cell over the 4-min period of observation is shown on the right. (E) Kymographs showing the time evolution of fluorescence signals along the yellow lines in the lower right panel of (C) depict the centripetal movement of Ag clusters and the surrounding actin structures. The velocity of a particle is proportional to the angle at which its track deviates from a vertical line along the time axis. See *Figure 1-Figure Supplement 1* for additional explanation of kymograph analysis. (F) A20 B cells expressing F-Tractin-GFP were added to anti-IgG-coated coverslips and the contact site was imaged every 2 s for 10 min using a Zeiss Airy Disk microscope. Images from *Video 3* are shown. Blue arrowheads represent a long-lived membrane protrusion. (G) A temporally-coded time series representing the edge of the cell (left) was generated from *Video 3* and the total area searched by the B cell over the 10-min period of observation is shown (right). Scale bars: 5 μm.

Figure 1–Figure supplement 1. Schematic of kymograph analysis.

min of contact with an APC, the control siRNA-transfected B cell shown in *Figure 2*A had coalesced
all of the Ag into 4 clusters, one of which contained 97.7% of the Ag fluorescence (*Figure 2*C). By
contrast, a similar amount of Ag was distributed among 16 distinct clusters in the Arp3 siRNA-
transfected cell depicted in *Figure 2*A, and no individual cluster contained more than 43% of the
total Ag fluorescence (*Figure 2*C). Similar results were obtained when comparing the CK-689-treated
(control) and CK-666-treated cells from *Figure 2*B (*Figure 2*D). Again, the control cell formed a cSMAC
into which ~95% of the Ag was gathered whereas no cluster in the CK-666-treated cells contained
more than 22% of the Ag fluorescence. For all B cells analyzed in this manner, the number of
BCR-Ag microclusters formed after 10 min in contact with an APC, as well as the distribution of the
total Ag fluorescence among individual clusters, is shown in *Figure 2-Figure Supplement 5*.

The failure to form a cSMAC when the Arp2/3 complex is depleted or inhibited was due to
decreased merger of individual BCR microclusters into larger clusters. Consistent with this idea, the
average size of BCR-Ag microclusters increased steadily over time in control cells as the microclusters
merged but remained relatively unchanged over the 14 min of imaging in the Arp3 siRNA-treated
cells and CK-666-treated cells (*Figure 2*E,F). Consequently, because microclusters merged, the
number of individual microclusters per cell decreased over time in the control cells but remained
similar, or increased, when Arp2/3 complex activity was inhibited (*Figure 2-Figure Supplement*
*4*C,D). Thus, BCR-mediated gathering of APC-bound Ags into a cSMAC at the center of the synapse
is strongly dependent on the functions of the Arp2/3 complex.

The Arp2/3 complex is important for BCR-induced actin reorganization and dynamics

To understand how the Arp2/3 complex promotes BCR microcluster centralization and cSMAC for-
mation, we sought to define its role in actin organization and dynamics at the contact site between
a B cell and an Ag-bearing surface. Ags or anti-Ig antibodies that are immobilized on coverslips are
widely-used model systems for imaging BCR-induced spreading and actin reorganization with high
resolution. To assess the role of the Arp 2/3 complex in this response, we used stimulated emis-
sion depletion (STED) microscopy. A20 B cells that bound to anti-IgG coated coverslips extended
broad lamellipodia and exhibited radial spreading (control siRNA cells in *Figure 3*A, *Figure 3-Figure*
Supplement 1, CK-689-treated cells in *Figure 3*B). This cell morphology was characterized by a
dense peripheral ring of highly-branched F-actin surrounding an actin-depleted central area that
contained thin actin filaments (*Figure 3*A,B, *Figure 3-Figure Supplement 1*). Within the peripheral
branched actin network of the lamellipodia, linear actin filaments, which may be nucleated by
formins, extended perpendicularly from the edge of the cell to the inner face of the peripheral
actin ring (*Figure 3*A,B, *Figure 3-Figure Supplement 1*A [yellow arrowheads]). We also observed long,
linear actin filaments that formed actin arcs running parallel to the inner face of the peripheral
ring of branched actin (*Figure 3*B [green arrowheads]; *Figure 3*E, *Figure 3-Figure Supplement 1*),
which were associated with myosin IIA (*Figure 3-Figure Supplement 1B*). These are similar to the

Figure 2. Arp2/3 complex function is important for centralization of BCR-Ag microclusters. (A,B) A20 D1.3 B cells were transfected with control siRNA or Arp3 siRNA (A) or pre-treated for 1 hr with 100 μM of either the control compound CK-689 or the Arp2/3 complex inhibitor CK-666 (B). The cells were then added to HEL-GFP-expressing COS-7 APCs and the B cell-APC contact site was imaged every 12 s for 10 min by spinning disk microscopy. Images are from *Video 4* (Control siRNA) and *Video 5* (Arp3 siRNA) or *Video 6* (CK-689) and *Video 7* (CK-666). The percent of cells for which >90% of the total Ag fluorescence intensity was contained in 1 or 2 clusters is graphed. n >35 cells from 4 independent experiments combined (A); n >18 cells from 3 independent experiments combined (B). *Figure 2 continued on next page.*

Figure 2 continued. (C,D) For the control siRNA- and Arp3 siRNA-transfected cells in (A), or the CK-689- and CK-666-treated cells in (B), binary representations of the Ag clusters present after 10 min of APC contact are shown. The graphs depict the percent of the total Ag fluorescence intensity, in arbitrary units (AU), present in individual clusters. The numbers to the right are the total number of Ag clusters at 10 min. (E,F) Control siRNA- and Arp3 siRNA-transfected A20 D1.3 B cells (E) or CK-689- and CK-666-treated A20 D1.3 B cells (F), were added to HEL-GFP-expressing COS-7 APCs and imaged every 12 s for 14 min by spinning disk microscopy. For each B cell, the average size of the BCR-Ag microclusters was determined for every frame in the video. The data are plotted as the mean (line) ± SEM (shaded area). In (E), n = 35 cells (control) or 48 cells (Arp3 siRNA) from 4 experiments. In (F), n = 18 cells (CK-689) or 20 cells (CK-666) from 3 experiments. The Mann-Whitney U test was used to calculate p values. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. Scale bars: 5 µm.

Figure 2–Figure supplement 1. siRNA-mediated knockdown of Arp3 in A20 B cells.

Figure 2–Figure supplement 2. CK-666 treatment does not decrease cell viability.

Figure 2–Figure supplement 3. CK-666 does not alter actin organization or dynamics in the COS-7 APCs.

Figure 2–Figure supplement 4. The Arp2/3 complex is important for the coalescence of BCR-Ag microclusters into a cSMAC.

Figure 2–Figure supplement 5. Distribution of total Ag fluorescence intensity in individual clusters.

---

actomyosin arcs that have been described in T cells (*Murugesan et al., 2016*).

This actin organization at the Ag contact site was strongly dependent on Arp2/3 complex activity.

When we depleted Arp3 with siRNA (*Figure 3*A), or inhibited the Arp2/3 complex in A20 B cells

using CK-666 (*Figure 3*B), BCR-induced spreading and actin reorganization were dramatically altered.

Unlike the control A20 B cells, which formed a highly dense, sheet-like actin network at the periphery,

Arp3-depleted and CK-666-treated B cells extended long and loosely packed filopodia-like fibers

(*Figure 3*A,B). This aberrant actin reorganization resulted in substantially reduced cell spreading on

anti-IgG coated coverslips (*Figure 3*C,D).

Because branched actin structures that are nucleated by the Arp2/3 complex exert forces on the

plasma membrane, we hypothesized that retrograde flow of actin would be disrupted in B cells

treated with the Arp2/3 inhibitor. To test this, A20 B cells expressing F-tractin-GFP were treated

with CK-689 or CK-666 and then added to anti-IgG-coated coverslips. Total internal reflection

fluorescence structured illumination microscopy (TIRF-SIM) was used to image actin dynamics with

high spatial and temporal resolution. In control CK-689-treated cells, the F-actin networks were

highly dynamic at the cell edge, with actin retrograde flow rates of ~2.5 µm/min (*Figure 3*E, *Video 8*).

In contrast, in B cells treated with the Arp2/3 complex inhibitor, the peripheral actin structures were

nearly static (*Figure 3*, *Video 9*). Thus, Arp2/3 complex function is essential for BCR-induced actin

reorganization and for peripheral actin dynamics.

Arp2/3 complex-dependent actin dynamics and membrane retraction drive BCR

microcluster centralization

How specific actin architectures allow B cells to scan APC membranes and then centralize the

resulting BCR microclusters into a cSMAC is not known. To test the role of Arp2/3-nucleated

actin networks in these processes, we used ISIM to simultaneously image actin structures and

BCR-Ag microclusters in F-Tractin-GFP-transfected A20 D1.3 B cells interacting with mHEL-HaloTag-

expressing COS-7 cells. As shown in *Video 2* and *Video 10*, control B cells extended dynamic,

transient actin-rich protrusions over the surface of the APC, with both lamellipodial and filopodia-

like structures being observed (see also *Figure 4*A, *Figure 5*A). Moreover, the high spatiotemporal

resolution of ISIM revealed that BCR-Ag microclusters were embedded within actin-rich protrusions

and moved towards the cell body as these protrusions were retracted (*Figure 4*A, *Figure 5*A, *Figure*

4-Figure Supplement 1, *Video 10*; see also *Figure 1*C). For example, the microcluster highlighted

in *Figure 5*A is encaged within an actin rich protrusion. In contrast, B cells that were treated with

the Arp2/3 complex inhibitor CK-666 primarily extended long, linear, filopodia-like actin structures

over the surface of the APC (*Figure 4*A, *Figure 5*A, *Figure 4-Figure Supplement 1*, *Video 11*). Most of

these actin structures did not retract towards the cell body over the 6.5 min observation period.

Moreover, BCR-Ag microclusters that formed on these protrusions did not translocate towards

the center of the synapse or merge with other microclusters (*Figure 4*A, *Figure 5*A, *Figure 4-Figure*

Figure 3. The Arp2/3 complex is important for BCR-induced actin reorganization and dynamics. (A,B) A20 B cells were transfected with either control siRNA or Arp3 siRNA (A) or pre-treated for 1 hr with 100 μM of the control compound CK-689 or the Arp2/3 complex inhibitor CK-666 (B). Cells were then allowed to spread on anti-IgG-coated coverslips for the indicated times before being fixed, stained for actin, and imaged by STED microscopy. Images representative of >20 cells per condition are shown. Yellow arrowheads indicate linear actin structures embedded within the peripheral branched actin network. Green arrowheads indicate actin arcs. Scale bars: 5 μm. For the regions within the yellow boxes, the images were enlarged (scale bars: 2 μm) and the relative densities of the actin structures are shown as heat maps. *Figure 3 continued on next page.*

Figure 3 continued. (C,D) A20 B cells were transfected with either control siRNA or Arp3 siRNA (C) or pre-treated for 1 hr with μM CK-689 or CK-666 (D). The cells were then allowed to spread on anti-IgG-coated coverslips for the indicated times before being stained for F-actin. The B cell-coverslip contact site was imaged using spinning disk microscopy. The cell area was quantified, using F-actin to define the cell edge. For each data point the mean ± SEM is shown for >27 cells from a representative experiment. ****p<0.0001; **p<0.01; *p<0.05; ns, not significant; Mann-Whitney U test. (E) A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with CK-689 or CK-666 and then added to anti-IgG-coated chamber wells. After 5 min, the cells were imaged by TIRF-SIM at 1 s intervals for 1 min. The left panels are the first images from *Video 8* (CK-689-treated cells) and *Video 9* (CK-689-treated cells), respectively (Scale bars: 5 μm). Yellow arrowheads indicate linear actin structures embedded within the peripheral branched actin network. Green arrowheads indicate actin arcs. The middle panels are enlargements of the areas within the yellow boxes in the left panels (Scale bars: 2 μm). The right panels are kymographs along the yellow dotted lines in the middle panels.

Figure 3–Figure supplement 1. Actin and myosin structures in A20 B cells spreading on immobilized anti-IgG.

---

*Supplement 1*A, *Video 11*).

Although the architectures of the actin protrusions generated by control and CK-666-treated

cells were dramatically different, the cells explored roughly the same area of the APC surface over

the period of observation (*Figure 4*B-E, *Figure 4-Figure Supplement 1*B). This is in contrast to the

significantly reduced cell spreading on rigid anti-Ig-coated surfaces that was observed when the

Arp2/3 complex was depleted or inhibited (*Figure 3*). Thus, Arp2/3 complex activity is requred

for B cells to spread on rigid surfaces but may be dispensable for B cells to effectively probe

the APC surface and form BCR-Ag microclusters under the conditions tested. However, Arp2/3

complex-mediated actin polymerization, and the resulting actin retrograde flow, appears to be

essential for the centralization of BCR-Ag microclusters. Consistent with this idea, kymograph

analysis showed that peripheral BCR-Ag clusters in control cells moved towards the center of the

synapse together with, and at a similar velocity as, the surrounding actin structures (*Figure 5*B,

*Figure 4-Figure Supplement 1*C). In contrast, when the Arp2/3 complex was inhibited, both the

BCR-Ag clusters and the associated actin structures were relatively immobile (*Figure 5*B, *Figure*

*4-Figure Supplement 1*C). Taken together, these data suggest that Arp2/3 complex-dependent actin

structures encage BCR-Ag microclusters, such that the actin retrograde flow drives their initial

centripetal movement. This appears to be required for the subsequent formation of a cSMAC,

which occurs in the actin-depleted central region of the cell.

Arp2/3 complex activity amplifies BCR signaling at the immune synapse

How the spatial organization of the BCR at the immune synapse impacts BCR signaling and B

cell activation is not fully understood. Because inhibition of the Arp2/3 complex prevented the

centripetal movement of BCR microclusters into a cSMAC but did not significantly alter the amount

of Ag gathered into BCR microclusters (*Figure 2*C, *Figure 2-Figure Supplement 4*A,B, *Figure 6-Figure*

*Supplement 1*A), this allowed us to ask whether the Arp2/3 complex-dependent spatial patterning

of BCR-Ag microclusters impacts BCR signaling output. We quantified proximal BCR signaling events

at the contact site between *ex vivo* primary murine splenic B cells and COS-7 APCs expressing a

single-chain anti-Igκ surrogate Ag on their surface (*Freeman et al., 2011*). A critical initial step in BCR

signaling is phosphorylation of the tyrosine residues within the immunoreceptor tyrosine-based

activation motifs (ITAMs) present in the CD79a/b signaling subunit of the BCR (*Dal Porto et al., 2004*).

This is required for the recruitment and activation of Syk, a tyrosine kinase that phosphorylates

multiple proteins that are critical for BCR signaling and B cell activation.

APC-induced phosphorylation of CD79a/b at the immune synapse was assessed by staining with

an antibody that recognizes the phosphorylated ITAMs of both CD79a and CD79b. We found that

CD79 phosphorylation occurred rapidly at the B cell-APC contact site and co-localized with BCR-Ag

clusters, which were detected using an antibody that detects the surrogate Ag (*Figure 6*A). As shown

in *Figure 2*, the BCR-Ag microcluster coalesced into a tight cSMAC within 5-10 min in control cells but

not in B cells treated with the Arp2/3 complex inhibitor CK-666 (*Figure 6*A). Using quantitative image

analysis, we then determined the relationship between the amount of Ag gathered into clusters

and the signaling output at those BCR-Ag microclusters. For each B cell, the total phospho-CD79

Figure 4. The Arp2/3 complex is important for actin and BCR microcluster dynamics at the B cell-APC immune synapse. (A-C) A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 µM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were imaged every 6.6 s for 6 min using ISIM. Images from *Video 10* and *Video 11* are shown in (A). Arrowheads indicate new protrusion events. The yellow boxes indicate the regions that are enlarged in *Figure 5*. *Figure 4 continued on next page.*

Figure 4 continued. In (B) the cell edge from each frame in *Video 10* (CK-689-treated cells) or *Video 11* (CK-666-treated cells), as defined by the peripheral F-actin, was overlaid as a temporally-coded time series (left). The total area searched by the B cell over the 6-minute period of observation is shown the right. In (C) the B cell-APC contact area is shown as a function of time for the cells in (A) (solid lines), and for another set of representative cells (dashed lines; images are shown in *Figure 4-Figure Supplement 1*). (D,E) A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 μM CK-689 or CK-666 and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were fixed at the indicated times and imaged by spinning disk microscopy. Representative images are shown (D) and the B cell-APC contact area (mean ± SEM), as defined by F-actin, is graphed (E). For each data point, n >20 cells from 3 independent experiments except for the 1 min time point (n = 4 cells). ns, not significant (p=0.7219, p=0.1310, p=0.0722, p=0.1443, p=0.2930, p=0.6263 for the 1, 3, 5, 10, 15, and 30 min time points, respectively); two-tailed paired t-test. Scale bars: 5 μm.

Figure 4–Figure supplement 1. Arp2/3 complex activity is required for actin dynamics and for the centripetal movement of BCR-Ag microclusters at the periphery of the B cell-APC contact site.

(pCD79) or phospho-Syk (pSyk) fluorescence intensity present in clusters at the B cell-APC interface
was divided by the total fluorescence intensity of clustered Ag. In control B cells treated with CK-689,
pCD79 levels were maximal at 5 and 10 min after the B cells were added to the APCs and declined
thereafter (*Figure 6*B), perhaps due to the internalization of BCR-Ag microclusters. Importantly, B
cells treated with the Arp2/3 complex inhibitor exhibited significantly lower pCD79 levels at the 5,
10, and 15 min time points compared to control cells (*Figure 6*B, *Figure 6-Figure Supplement 1*B).
Similar results were obtained when HEL-specific B cells from MD4 mice were added to COS-7 APCs
expressing the HEL-HaloTag Ag (*Figure 6-Figure Supplement 1*C,D).
We also analyzed CD79 phosphorylation by immunoblotting, which would detect BCRs on the
cell surface as well as ones that have been internalized. Indeed, immunoblotting showed that
APC-induced CD79 phosphorylation increased continually over the first 30 min of B cell-APC contact
(*Figure 6*C). Importantly, similar to what was observed by imaging the B cell-APC interface, treating
the B cells with CK-666 reduced APC-induced CD79 phosphorylation, especially at the 15 and 30
min time points (*Figure 6*C, *Figure 6-Figure Supplement 2*A). In contrast, CK-666 treatment did not
impair the ability of soluble anti-Ig antibodies to stimulate CD79 phosphorylation (*Figure 6*D, *Figure
6-Figure Supplement 2*B). This suggests that the Arp2/3 complex-dependent spatial patterning of
BCR-Ag microclusters amplifies proximal BCR signaling in response to polarized, membrane-bound
Ags but not soluble Ags.
The Ag-induced binding of Syk to phosphorylated CD79a/b leads to the phosphorylation of
Syk (*Rowley et al., 1995*). Phosphorylation on Y342 and Y346 increases Syk activity and generates
binding sites for PLCγ2 and Vav (*Geahlen, 2009*). When *ex vivo* primary B cells interacted with APCs
expressing the single-chain anti-Igκ surrogate Ag, co-localization of pSyk (Y346) with BCR-Ag clusters
was observed within 3 min (*Figure 6*E, *Figure 6-Figure Supplement 3*A). B cells treated with CK-666
had significantly lower levels of pSyk at 3 min and 5 min after contacting the APCs, compared
to control cells (*Figure 6*F). Similar results were obtained when HEL-specific primary B cells were
added to APCs expressing the HEL-HaloTag Ag (*Figure 6-Figure Supplement 3*B,C). Together, these
data suggest that the Arp2/3 complex is required for the amplification of the earliest BCR signaling
events, phosphorylation of the CD79a/b ITAMs and phosphorylation of tyrosine residues in Syk that
are required for its activation.

Inhibiting the Arp2/3 complex increases tonic BCR signaling and BCR diffusion
Although treating B cells with the Arp2/3 complex inhibitor reduced the ability of APC-bound Ags to
stimulate the phosphorylation of CD79 and Syk, CK-666-treated B cells exhibited higher levels of
pCD79 prior to Ag encounter (*Figure 6*C,D; 0 min time point). This was accompanied by increased
phosphorylation of ERK and Akt, downstream targets of BCR signaling (*Figure 7*A). Actin-based
diffusion barriers restrict the lateral mobility of the BCR within the plasma membrane and increased
BCR mobility is associated with increased tonic, i.e. Ag-independent, BCR signaling (*Freeman et al.,
2015*; *Treanor et al., 2010*). Because Arp2/3 complex activity contributes to the formation of the
submembrane cortical actin network, which creates diffusion barriers for transmembrane proteins,

Figure 5. Arp2/3 complex-dependent actin structures encage BCR-Ag microclusters on membrane protrusions. (A) Images from *Video 10* and *Video 11* showing enlargements of the regions indicated by the yellow boxes in *Figure 4*. A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were imaged every 6.6 s for 6 min using ISIM. Scale bars: 2 μm. (B) The kymographs represent a time series of images taken along the white dashed lines in (A).

Figure 6. The Arp2/3 complex amplifies proximal BCR signaling. (A,B) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Igκ surrogate Ag. The cells were fixed at the indicated times and stained with an antibody that recognizes the surrogate Ag and with an antibody that recognizes the phosphorylated ITAMs in CD79a and CD79b (pCD79). Images of representative cells are shown (A). For each B cell, the total fluorescence intensity of clustered pCD79 was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. Beeswarm plots in which each dot is one cell. The median (red line) and interquartile ranges (red box) for >39 cells for each time point from a representative experiment are shown (B). *Figure 6 continued on next page.*

Figure 6 continued. (C,D) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Igκ surrogate Ag (C) or stimulated with 10 μg/ml soluble anti-Igκ (D) for the indicated times. pCD79 and total CD79a immunoblots are shown (left panels) and the pCD79/total CD79a ratios are graphed (right panels). Dotted red line corresponds to the pCD79/total CD79a ratio value for unstimulated CK-689-treated B cells. Representative data from one of 7 experiments. An additional independent experiment is shown in *Figure 6-Figure Supplement 2*. See *Figure 9-Figure Supplement 6* for full blots. (E,F) Primary murine B cells that had been pre-treated with 100 μM CK-689 or CK-666 for 1 hr were added to COS-7 cells expressing the single-chain anti-Igκ Ag. The cells were fixed at the indicated times and stained for the surrogate Ag and pSyk (E). For each B cell, the total fluorescence intensity of clustered pSyk was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. Beeswarm plots with the median and interquartile ranges for >112 cells for each time point from a representative experiment are shown (F). ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns, not significant; Mann-Whitney U test. Scale bars: 2 μm.

Figure 6–Figure supplement 1. Arp2/3 complex activity amplifies CD79 phosphorylation.

Figure 6–Figure supplement 2. Additional independent experiment associated with Figure 6C,D.

Figure 6–Figure supplement 3. Arp2/3 complex activity amplifies Syk phosphorylation.

---

we tested the hypothesis that Arp2/3 complex activity limits Ag-independent BCR signaling by
restricting BCR mobility prior to Ag encounter. We used single-particle tracking (SPT) to compare
the diffusion and confinement properties of both IgM- and IgD-containing BCRs, in control versus
CK-666-treated primary B cells. Indeed, the median diffusion coefficients for IgM and IgD were ap-
proximately 2.8-fold higher in CK-666-treated cells than in control CK-689-treated cells (*Figure 7*B-D).
Consistent with their increased lateral mobility, both IgM and IgD had larger effective confinement
diameters in CK-666-treated cells than in control CK-689-treated cells (*Figure 7*B-D). Thus, CK-666
treatment increases both BCR mobility and tonic BCR signaling. This suggests that the Arp2/3
complex contributes to the formation of actin-based barriers that normally limit BCR diffusion and
tonic BCR signaling.

Arp2/3 complex activity is important for BCR-CD19 interactions

CD19 is essential for B cell activation by membrane-bound Ags but not soluble Ags (*Depoil et al.,*
2008; *Xu et al., 2014*). Initial BCR signaling leads to phosphorylation of CD19 on key tyrosine residues,
allowing CD19 to recruit PI3K and Vav (*Buhl et al., 1997*; *O'Rourke et al., 1998*; *Tuveson et al., 1993*).
CD19 is relatively immobile within the plasma membrane and this facilitates BCR-CD19 interactions
and CD19-dependent amplification of BCR signaling (*Mattila et al., 2013*). Indeed, depolymerizing
the actin cytoskeleton results in diminished CD19 phosphorylation and PI3K signaling in response to
BCR stimulation (*Keppler et al., 2015*; *Mattila et al., 2013*). Using SPT, we found that treating B cells
with CK-666 caused a 2.3-fold increase in the median diffusion coefficient for CD19 and increased
its effective confinement diameter (*Figure 8*A). This suggests that Arp2/3 complex-dependent actin
structures limit the lateral mobility of CD19 in the plasma membrane, which may be important for
membrane-bound Ags to stimulate CD19 phosphorylation and augment BCR-CD19 interactions.

To test this, we asked whether inhibiting Arp2/3 complex activity altered the ability of membrane-
bound Ags to stimulate CD19 phosphorylation. We used phospho-specific antibodies to detect
CD19 that is phosphorylated on Y531 (pCD19) and quantified the level of pCD19 at the contact site
between primary splenic B cells and APCs expressing the single-chain anti-Igκ surrogate Ag (*Fig-*
*ure 8*B,C). We found that the initial peak of APC-induced CD19 phosphorylation was diminished and
delayed in CK-666-treated B cells, compared to the control CK-689-treated cells (*Figure 8*C, *Figure*
*8-Figure Supplement 1*A). As observed for phosphorylation of CD79, inhibiting the Arp2/3 complex
did not impair the ability of soluble anti-Ig antibodies to stimulate rapid and robust CD19 phos-
phorylation (*Figure 8-Figure Supplement 1*B). This suggests that Arp2/3 complex-dependent actin
structures provide spatial organization that is important for BCR-induced CD19 phosphorylation in
response to spatially-restricted membrane-bound Ags.

Because the co-localization of pCD19 with the BCR could determine the extent to which CD19
amplifies BCR signaling, we next quantified the fraction of total pCD19 fluorescence that over-
laps BCR-Ag microclusters, using the Manders' coefficient. In control cells, much of the pCD19
fluorescence occured within BCR-Ag clusters at all time points after initiating B cell-APC contact

Figure 7. The Arp2/3 complex regulates BCR mobility and tonic signaling in resting B cells. (A) *Ex vivo* primary murine B cells were treated with DMSO, 100 μM CK-689, or 100 μM CK-666 for 1 hr, or stimulated with anti-Igκ antibodies for 5 min. Cell extracts were analyzed by immunoblotting with antibodies against phospho-ERK (pERK) and total ERK, or phospho-Akt (pAkt) and total Akt. Representative blot are shown (left). Band intensities were quantified and the ratio of pERK/total ERK and pAkt/total Akt (right) relative to those in anti-Igκtreated cells (=1.0) are graphed as the mean ± SEM for 4 (pERK) or 5 (pAkt) independent experiments. Two-tailed paired t-test. See *Figure 9-Figure Supplement 6* for full blots. (B-D) *Ex vivo* primary murine splenic B cells were treated with 100 μM CK-689 or CK-666 for 1 hr. SPT was then carried out by labeling the cells at low stoichiometry with Cy3-labeled Fab fragments of antibodies to IgM (B) or IgD (C). The cells were then settled onto non-stimulatory anti-MHC II-coated coverslips and imaged for 10 s at 33 Hz by total internal reflection florescence microscopy (TIRFM). Single-particle trajectories from representative cells are plotted using a color-coded temporal scale (left panels). Scale bars: 5 μm. Diffusion coefficients were calculated for the indicated number of tracks and cumulative frequency curves are shown (center panels). The diameter of maximum displacement over the 10-second period of observation (confinement diameter) was calculated for each track and cumulative frequency curves are shown (right panels). The dots on the curves indicate the median values. Representative data from one of 3 independent experiments ****p<0.0001; Kolmogorov-Smirnov test.

(*Figure 8*D). The pCD19-Ag overlap was significantly less in the CK-666-treated B cells than in the
control cells at all time points. By contrast, the overlap between pSyk clusters and BCR-Ag clusters
in CK-666-treated cells was either not significantly different from, or was slightly higher, than in
control cells over the first 15 min of B-APC interactions (*Figure 8-Figure Supplement 1*C). Thus,
unlike pSyk, which is strongly associated with signaling BCRs, the co-localization of pCD19 with
the BCR is impacted by Arp2/3 complex activity. Importantly, we found that the total amount of
pCD19 fluorescence that overlapped with BCR-Ag clusters was much lower in CK-666 treated cells
than in control cells at the 3 min time point. This reflects both decreased CD19 phosphorylation
and decreased BCR-pCD19 overlap in the CK-666-treated cells. As for total pCD19 fluorescence,
the initial peak of pCD19 fluorescence within BCR-Ag microclusters was diminished and delayed
when Arp2/3 complex activity was inhibited (*Figure 8*E). Taken together, these findings indicate that
actin networks nucleated by the Arp2/3 complex promote APC-induced CD19 phosphorylation and
enhance the interaction of pCD19 with the BCR.

Arp2/3 complex activity is important for BCR-induced B cell activation responses

We next sought to determine if the early BCR signaling defects observed in B cells treated with
the Arp2/3 complex inhibitor translated into reduced B cell activation responses at later times.
In *Figure 9*, we show that COS-7 APCs expressing the single chain anti-Igκ surrogate Ag induce
primary B cells to undergo robust transcriptional responses, activation marker upregulation, cell
size increase, and proliferation. We then assessed whether inhibiting Arp2/3 complex activity by
treating the cells with CK-666 impacted these BCR-mediated responses that occur after 3-72 hr of
Ag stimulation (*Figure 9*A).

To assess BCR-induced transcriptional responses, we used B cells from Nur77^{GFP} reporter mice
in which GFP expression is under the control of the *Nur77* promoter (*Moran et al., 2011*). *Nur77* is
an immediate early gene whose transcription is induced in lymphocytes by TCR or BCR engagement.
Primary Nur77^{GFP} B cells were incubated with COS-7 cells expressing the single chain anti-Igκ
surrogate Ag, or with parental COS-7 cells (no surrogate Ag), in the presence CK-689 or CK-666. GFP
expression was measured by flow cytometry after 3 hr (see *Figure 9-Figure Supplement 1* for gating
strategy). In the absence of surrogate Ag expression by the COS-7 cells, Nur77^{GFP} B cells did not
adhere to the COS-7 cells and GFP expression was not increased relative to B cells that were cultured
in the absence of COS-7 cells (*Figure 9-Figure Supplement 1*B,C). By contrast, culturing Nur77^{GFP} B
cells with anti-Igκ-expressing COS-7 cells resulted in increased GFP expression compared to B cells
that were cultured with parental COS-7 cells. Importantly, in the presence of the Arp2/3 inhibitor
CK-666, this APC-induced increase in GFP expression was reduced to ~30% of the levels observed in
control Nur77^{GFP} B cells treated with CK-689 (*Figure 9*B).

In the presence of APC-bound Ags, inhibition of Arp2/3 complex activity also impaired the ability
of primary B cells to increase their cell surface levels of CD69, the canonical marker of lymphocyte
activation, and CD86, a co-stimulatory ligand critical for T cell activation (*Figure 9*C,D). Culturing
primary B cells with anti-Igκ-expressing COS-7 APCs for 18 hr resulted in increased expression
of CD69 and CD86 on the B cells (*Figure 9*C,D), responses that were completely dependent on
expression of the surrogate Ag on the APCs (*Figure 9-Figure Supplement 2*). In CK-666-treated B
cells, BCR-induced upregulation of CD69 and CD86 was inhibited by 40-50%. This was not due to
increased B cell death, as DAPI-positive dead cells were excluded from analysis (*Figure 9-Figure
Supplement 2*). Importantly, CD86 upregulation in response to PMA plus ionomycin was not affected
by CK-666 (*Figure 9*E). Similar results were obtained for CD69 (data not shown). This suggests that
inhibiting the Arp2/3 complex impairs proximal BCR signaling that is important for upregulation of
CD86, as opposed to downstream events that are induced by both PMA plus ionomycin and BCR
engagement.

In this co-culture system, both the B cells and the APCs are exposed to CK-666 for the entire
duration of the experiment. To ensure the observed reduction in CD69 and CD86 expression was not
due to effects of CK-666 on the APCs, we used Arp3 siRNA to deplete the Arp2/3 complex in B16F1

Figure 8. The Arp2/3 complex regulates CD19 mobility and BCR-CD19 interactions. (A) *Ex vivo* primary murine splenic B cells were treated with 100 μM CK-689 or CK-666 for 1 hr. SPT was then carried out as in *Figure 7*, using Cy3-labeled Fab fragments of antibodies to CD19. Single-particle trajectories from a representative cell are plotted using a color-coded temporal scale (left panels). Scale bars: 5 μm. Diffusion coefficients (center panels) and the diameter of maximum displacement (confinement diameter, right panels) over the 10-second period of observation were calculated for each track and cumulative frequency curves are shown. The dots on the curves indicate the median values. ****p<0.0001; Kolmogorov-Smirnov test. (B-E) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Igκ surrogate Ag. Cells were fixed at the indicated time points and stained with an antibody that recognizes the surrogate Ag and with an antibody that recognizes phosphorylated CD19. Representative cells are shown (B). Scale bars: 2 μm. For each B cell, the total fluorescence intensity of clustered pCD19 was calculated. Beeswarm plots in which each dot represents one cell are plotted with the median (red line) and interquartile ranges (red box) for >125 cells per time point from a representative experiment (C). For each cell in (C) the fraction of total pCD19 fluorescence that overlaps with BCR-Ag microclusters was quantified by calculating the Manders' coefficient (D). For each cell in (C) the total fluorescence intensity of pCD19 that was within BCR-Ag microclusters in cells was quantified (E). ****p<0.0001; ***p<0.001; ns, not significant; Mann-Whitney U test.

Figure 8–Figure supplement 1. Arp2/3 complex activity increases CD19 phosphorylation in response to membrane-bound Ags.

murine melanoma cells expressing the single chain anti-Igκ Ag (*Figure 9-Figure Supplement 3*A,B). When primary B cells were added to these APCs, we observed that control and Arp3-depleted B16F1 APCs induced the upregulation of CD69 and CD86 to the same extent (*Figure 9-Figure Supplement 3*C,D). Moreover, B cells treated with CK-666 exhibited similarly impaired CD69 and CD86 responses, regardless of whether Arp3 was depleted or not in the APCs (*Figure 9-Figure Supplement 3*E,F). This indicates that the impaired upregulation of CD69 and CD86 observed in CK-666 treated cells is B cell-intrinsic.

Because the CK-666 was present during the entire B cell-APC co-culture in these experiments, it was also important to determine whether the impaired responses to APC-bound Ags were due to alterations in the initial BCR spatial reorganization and signaling, or to later events. To test this, we delayed the addition of CK-666. Pre-treating B cells with CK-666 for 1 hr prior to adding them to the APCs resulted in substantial inhibition of CD69 upregulation (*Figure 9*C). However, if the CK-666 was added 5 min after initiating the B cell-APC co-culture, or at later time points, it had very little effect on the BCR-induced upregulation of CD69 (*Figure 9*F). Adding CK-666 to the B cells at same time that they were mixed with the APCs caused only partial inhibition of the CD69 response compared to pre-treating the B cells for 1 hr with the drug. Similar results were obtained for CD86 (data not shown). This likely reflects the fact that some time is required for the CK-666 concentration in the B cells to reach a level that substantially inhibits Arp2/3 complex activity. Hence APC-induced B cell activation is only impaired if Arp2/3 complex activity is inhibited during the initial stages of B cell-APC interaction. Moreover, if CK-666 was present during the initial B cell-APC interaction, and then washed out after 5-120 min, CD69 upregulation was able to recover to nearly 100% of control values, regardless of when the washout was performed (*Figure 9-Figure Supplement 4*A). Once the drug was removed, the cells recovered their ability to aggregate BCR microclusters and form a cSMAC (*Figure 9-Figure Supplement 4*B-D) and B cell activation could proceed normally, consistent with the effects of CK-666 on actin dynamics being rapidly reversible (*Yang et al., 2012*). Together, these results argue that Arp2/3 complex-dependent processes that occur during the initial stages of B cell-APC interactions are required for B cell activation responses.

Inhibition of the Arp2/3 complex results in dramatic alterations of the actin cytoskeleton at the immune synapse(*Figure 3*). It is possible that this disrupted actin architecture blocks contractile forces generated my myosin IIA (*Ennomani et al., 2016*). In T cells, contractile forces generated by myosin IIA are important for centralizing TCR microclusters into a cSMAC (*Babich et al., 2012*; *Ilani et al., 2009*; *Jacobelli et al., 2004*; *Kumari et al., 2012*; *Murugesan et al., 2016*; *Yi et al., 2012*). To assess the contribution of myosin contractility in our system, we treated primary B cells with para-nitro-blebbistatin (pnBB) to inhibit myosin. When pnBB treated cells were added to COS-7 APCs expressing membrane-bound anti-Igκ for 18 hr, they exhibited a slight, but not statistically significant reduction in CD69 and CD86 upregulation compared to DMSO-treated cells (*Figure 9-Figure Supplement 5*A,B). Moreover, pnBB-treated A20 D1.3 B cells that were added to COS-7 APCs expressing expressing mHEL-HaloTag were able to form cSMACs to the same extent as DMSO-treated cells (*Figure 9-Figure Supplement 5*A,B). These results suggest that APC-induced activation marker expression and cSMAC formation are dependent on Arp2/3 complex activity whereas myosin contractility has little or no involvement, at least under these experimental conditions.

As part of their activation program, B cells increase size as they enter S phase, reflecting an increase in the secretory machinery required for antibody synthesis (*DeFranco et al., 1985*; *Kirk et al., 2010*). Compared to resting lymphocytes, activated lymphoblasts exhibit an increase in both forward scatter (cell size) and side scatter (granularity) when analyzed by flow cytometry. Co-culturing primary B cells with anti-Igκ-expressing COS-7 APCs for 18 hr resulted in 30-55% of the B cells becoming larger, more granular blast cells (*Figure 9*G; *Figure 9-Figure Supplement 2*C,D). However, in the presence of the Arp2/3 complex inhibitor CK-666, the percent of B cells that became blast cells was reduced to 5-16% (*Figure 9*G).

In the presence of co-stimulatory cytokines such as BAFF and IL-4, Ag-activated B cells proliferate extensively. CFSE dilution assays showed that >90% of primary B cells that were co-cultured with

anti-Igκ-expressing COS-7 APCs plus these cytokines for 72 hr had divided (*Figure 9*H). Addition of
CK-666 to the culture reduced the percent of B cells that had divided at least once to ~55% and
the mean number of cell divisions was reduced from 2 to 0.7 (*Figure 9*H). This reduction in B cell
proliferation was accompanied by increased cell death (*Figure 9*H), which is the alternative fate for
B cells that are cultured *in vitro* in the absence of mitogenic stimuli. Note that when the Arp2/3
inhibitor CK-666 was added 24 hr after initiating the B cell-APC co-culture, B cell proliferation was
not impaired (*Figure 9*H, middle panel). This indicates that CK-666 does not block cell division and
suggests that the critical functions of the Arp2/3 complex in APC-dependent B cell activation occur
during the first 24 hr. Collectively, these findings indicate that the Arp2/3 complex-dependent
processes are important for B cells to enter S phase and proliferate.

Discussion

Using high spatiotemporal resolution imaging of actin in B cells interacting with APCs, we observed
that B cells scan the surface of the APC using complex and dynamic actin-rich protrusions that
constantly extend and retract across the APC surface. This dynamic probing is mediated by Arp2/3
complex activity, which also generates retrograde actin flow that facilitates the initial centripetal
movement of BCR microclusters and is required for cSMAC formation. Importantly, these Arp2/3
complex-dependent processes amplify proximal and distal BCR signaling, transcriptional responses,
and B cell proliferation in response to APC-bound Ag.
In contrast to the highly dynamic lamellipodia and filopodia that B cells extend asymmetrically
over the APC surface, the actin-rich protrusions that B and T cells form when they spread on Ag-
bearing lipid bilayers (*Fleire, 2006*; *Murugesan et al., 2016*) or Ag-coated coverslips (*Bunnell et al.,*
2001; *Freeman et al., 2011*) are predominantly symmetrical, sheet-like lamellipodia. This difference
in spreading and probing behavior may reflect the physical properties of the Ag-bearing substrate.
In fibroblasts and epithelial cells, stiffer substrates favor Rac1- and Arp2/3 complex-dependent
formation of lamellipodia whereas softer substrates favor Cdc42- and formin-dependent formation
of filopodia (*Collins et al., 2017*; *Wong et al., 2014*). The greater prevalence of filopodia when B
cells spread on APCs, compared to artificial lipid bilayers, is consistent with the finding that the
APC membrane is less stiff than the artificial lipid bilayers that have been used to mimic APCs
(*Natkanski et al., 2013*). Whether local variations in the stiffness of the APC membrane shape B
cell probing behavior is not known. However, the membranes of FDCs and dendritic cells differ in
their stiffness (*Spillane and Tolar, 2017*) and this could impact the type of probing behavior that B
cells use to scan the surface of these APCs.
The filopodia-like structures formed by control B cells interacting with APCs allowed the forma-
tion of BCR-Ag microclusters at sites distant from the cell body. Branched actin networks that were
nucleated around these linear protrusions then encased the BCR-Ag microclusters and generated
centripetal flow that was required for BCR-Ag microcluster centralization. When the Arp2/3 complex
was inhibited, lamellipodial branched actin protrusions were not generated in response to either
APC-bound Ag or anti-Ig-coated coverslips, and instead the formation of filopodia was greatly
enhanced. This is consistent with the idea that the Arp2/3 complex and formins compete for a
limited pool of actin monomers (*Suarez and Kovar, 2016*). In B cells in which the Arp2/3 complex
was inhibited, the filopodia that formed were able to extend over the surface of the APC and gather
Ag into microclusters. However, these filopodia and their associated BCR-Ag microclusters, were
not efficiently retracted towards the cell body.
We showed that Arp2/3 complex-dependent branched actin nucleation is essential for actin
retrograde flow at the cell periphery and is required for BCR-Ag microcluster centralization and
cSMAC formation. In T cells, both pushing forces generated by actin retrograde flow and contractile
forces generated by actomyosin arcs have been shown to drive the centripetal movement of
TCR microclusters to form a cSMAC (*Babich et al., 2012*; *Ilani et al., 2009*; *Jacobelli et al., 2004*;
Kumari et al., 2012; *Murugesan et al., 2016*; *Yi et al., 2012*). In B cells spreading on anti-Ig-coated
coverslips we observed similar actomyosin arcs formed at the inner face of the peripheral ring

Figure 9. Arp2/3 complex activity is required for B cell activation responses. (A) Readouts used to assess B cell activation in response to anti-Igκ-expressing APCs. Primary murine B cells were pre-treated with CK-689 or CK-666 for 1 hr and then added to the APCs. The CK-689 or CK-666 was present in the co-culture for the entire length of the experiment unless otherwise indicated. *Figure 9 continued on next page.*

Figure 9 continued. (B) Histograms showing GFP fluorescence in primary *ex vivo* Nur77^{GFP} B cells exposed to anti-Igκ-expressing COS-7 APCs (filled curves) or parental COS-7 cells (unfilled curves) for 3 hr. The Ag-induced increase in GFP fluorescence was calculated as the geometric mean for B cells cultured with anti-Igκ-expressing APCs (dotted line) minus the geometric mean for B cells cultured with parental COS-7 cells. See *Figure 9-Figure Supplement 1*A for gating strategy. The graph shows the Ag-induced increase in GFP fluorescence in CK-666-treated B cells as a percent of the response in CK-689-treated control cells (=100%). Each dot is an independent experiment and the red line is the median. (C,D) Histograms showing CD69 (C) or CD86 (D) upregulation in primary *ex vivo* C57BL/6J B cells exposed to anti-Igκ-expressing APCs (filled curves) or parental COS-7 cells (unfilled curves) for 18 hr. The Ag-induced increases in CD69 or CD86 expression were calculated as in (B). See *Figure 9-Figure Supplement 2* for gating strategy and representative calculations. Graphs show the increase in expression in CK-666-treated B cells as a percent of the response in CK-689-treated controls (=100%). Each dot is an independent experiment. The median (red line) and interquartile ranges (box) are shown. (E) Induction of CD86 expression in response to APCs (calculated as above) or to PMA + ionomycin (geometric mean for stimulated B cells minus geometric mean for unstimulated B cells) in the same experiment. Responses by CK-666-treated B cells are expressed as a percent of those in the CK-689-treated control cells. Results from 2 experiments are shown along with the average (bar). (F) B cells were pre-treated with CK-689 or CK-666 for 1 hr before being added to anti-Igκ-expressing APCs or parental COS-7 cells (-60 min time point). Alternatively, the drugs were added at the same time that the B cells (0 min) were added to the APCs or parental COS-7 cells, or at 5-60 min after initiating the co-culture. The Ag-induced increase in CD69 expression after 18 hr of co-culture was calculated as above and responses by CK-666-treated B cells are expressed as a percent of those in the CK-689-treated control cells. For each point, the average ± range is shown for 2 experiments. (G) B cells were pre-treated with CK-689 or CK-666 for 1 hr prior to being added to anti-Igκ-expressing APCs. After 18 hr of co-culture, the percent of blast cells with increased forward and side scatter was determined by flow cytometry (see *Figure 9-Figure Supplement 2* for gating strategy). Each dot is an independent experiment. The median (red line) and interquartile ranges are shown. (H) CFSE-labeled B cells were pre-treated with CK-689 or CK-666 for 1 hr prior to being cultured with APCs, IL-4, and BAFF for 3 days (filled curves). The unfilled curves depict CFSE dilution at Day 1. Representative data from one experiment is shown on the left and the average number of divisions per cell is indicated. The graph in the center shows the percent of live cells that had proliferated by Day 3. The percent of dead B cells that stained with 7-AAD is shown (right). Where indicated, CK-666 was added 24 hr after initiating the B cell-APC co-culture instead of 1 hr prior. In the graphs, each dot is an independent experiment and the bars indicate medians. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns, not significant. Two-tailed paired t-test.

Figure 9–Figure supplement 1. Gating strategy for GFP expression.

Figure 9–Figure supplement 2. Gating strategy for CD69 and CD86 upregulation and blast cell formation.

Figure 9–Figure supplement 3. Depletion of the Arp2/3 complex in APCs does not affect B cell activation responses

Figure 9–Figure supplement 4. Washout of CK-666 allows normal APC-induced upregulation of CD69 and cSMAC formation.

Figure 9–Figure supplement 5. Inhibition of myosin does not affect upregulation of B cell activation markers or cSMAC formation

Figure 9–Figure supplement 6. Images of full blots.

of branched actin. Consistent with the idea that these linear actin arcs are generated by formins, these structures appeared to form in B cells in which the Arp2/3 complex was inhibited, as has been observed in T cells (*Murugesan et al., 2016*). Myosin IIA is important for B cells to extract Ags from APC membranes (*Hoogeboom et al., 2018*; *Natkanski et al., 2013*) and has been implicated in BCR microcluster centralization (*Tolar, 2017*). However, inhibition of myosin IIA did not affect cSMAC formation or the upregulation of B activation markers in our system. Although this does not rule out a role for myosin in B cell immune synapse formation and APC-induced B cell activation, it highlights that the Arp2/3 complex has a more important role in these processes, at least in our experimental system.

TCR microcluster centralization and cSMAC formation in T cells has been proposed to involve three cytoskeleton-dependent mechanisms that act sequentially: actin retrograde flow, actomyosin contraction, and movement along microtubules that span the actin-poor central region of the immune synapse (*Kumari et al., 2014*). Dynein-dependent movement of BCR and TCR micro-clusters along juxtamembrane microtubules is required for cSMAC formation in both B and T cells (*Hashimoto-Tane et al., 2011*; *Schnyder et al., 2011*). We have shown that the formation of branched actin at the periphery of the immune synapse is required for capturing the plus ends of microtubules and for moving the microtubule network towards the Ag-presenting surface (*Wang et al., 2017*). In B cells spreading on anti-Ig-coated coverslips, microtubule plus end binding proteins contact the inner face of the dense peripheral actin ring, which is depleted of microtubules, much like the leading edge of a migrating cell. Hence, initial microcluster centralization mediated by Arp2/3 complex-dependent actin retrograde flow may be required for BCR microclusters to associate with microtubules and coalesce into a cSMAC at the center of the immune synapse. Thus, inhibiting Arp2/3 complex activity may block a critical initial step in BCR-Ag microcluster centralization and prevent the microtubule-based centralization that leads to cSMAC formation, the site where Ags are often internalized.

We showed that Arp2/3 complex activity amplifies BCR signaling in response to APC-bound Ags. The molecular mechanisms by which the actin cytoskeleton regulates Ag receptor signaling are still being explored. In T cells, actin retrograde flow is important for sustained TCR signaling in response to Ag-bearing artificial lipid bilayers (*Babich et al., 2012*; *Kumari et al., 2015*). Because the TCR is a mechanosensitive receptor, actin retrograde flow could exert tension on the TCR that enhances its signaling (*Basu and Huse, 2017*). The BCR is also highly sensitive to mechanical force, such that increasing the stiffness of Ag-presenting surfaces causes greater recruitment of Syk and other signaling components (*Wan et al., 2013*, *2015*). Hence, Arp2/3 complex-dependent actin retrograde flow could increase the mechanical tension on Ag-bound BCRs and enhance their signaling. Consistent with this idea, we observed that peak BCR signaling occurred during the first 5 min of APC encounter, when BCR-Ag microclusters are undergoing the greatest centripetal movement.

BCR signaling is enhanced by the formation of large and stable microclusters, which is dependent on Ag mobility and the actin cytoskeleton (*Ketchum et al., 2014*). In control B cells, microcluster size increased most rapidly between 2 and 6 min after the B cells were added to the APCs, which corresponds with the peak of proximal BCR signaling. Inhibition of the Arp2/3 complex decreased both microcluster merge events and BCR signaling, consistent with the idea that actin-dependent microcluster aggregation enhances BCR signaling. Microcluster growth may increase the frequency at which Ag-bound BCRs that have recruited Syk can trap BCRs that are not bound to Ag, and activate them via Syk-mediated phosphorylation. Alternatively, larger microclusters may more efficiently shield activated BCRs from negative regulators such as CD22 (*Gasparrini et al., 2016*).

Arp2/3 complex-dependent actin polymerization could also enhance BCR signaling by main-taining the integrity of the BCR-Ag microclusters and by acting as a platform for the assembly of signaling complexes. We observed that BCR-Ag microclusters were surrounded by actin cages. The idea that these cages maintain the integrity of BCR microclusters is supported by the finding that microclusters become more diffuse when B cells are treated with the actin-depolymerizing drug la-

trunculin A (*Treanor et al., 2011*). In T cells, signaling proteins such as PLCγ1 accumulate at actin foci
that surround TCR microclusters (*Kumari et al., 2015*). Deletion of WASp or inhibition of the Arp2/3
complex has no effect on proximal TCR signaling or microcluster formation but results in impaired
recruitment and activation of PLCγ1 (*Kumari et al., 2015*). Whether Arp2/3complex-dependent actin
structures surrounding BCR microclusters act as scaffolds that amplify and diversify BCR signaling
remains to be determined.

Although Ag-induced actin reorganization enhances BCR signaling, the submembrane actin
cytoskeleton limits the lateral mobility of the BCR in resting B cells and thereby prevents spon-
taneous BCR signaling. Indeed, disrupting the actin cytoskeleton with latrunculin A is sufficient
to induce robust Ag-independent BCR signaling (*Treanor et al., 2010*). We found that inhibiting
Arp2/3 complex activity in resting primary B cells resulted in increased basal levels of pERK and
pAkt, and that this correlated with increased lateral mobility of both IgM-BCRs and IgD-BCRs within
the plasma membrane. Hence, Arp2/3 complex-mediated actin polymerization is also important for
maintaining the quiescent state of resting B cells and for preventing aberrant Ag-independent BCR
signaling.

We also showed that Arp2/3 complex activity enhances functional interactions between the BCR
and its co-receptor CD19. Ag binding promotes the tyrosine phosphorylation of CD19, allowing it to
recruit key effectors of BCR signaling such as PI3K and Vav. CD19 associates with the Lyn tyrosine
kinase, which can phosphorylate the CD79a/b signaling subunit of the BCR, and has also been
reported to enhance recruitment the of Syk and Btk tyrosine kinases to the BCR (*Depoil et al., 2008*;
Fujimoto et al., 2000, *2002*). Hence, the interaction of the BCR with CD19 facilitates processive
signaling reactions that amplify BCR signaling. Consistent with APC-induced CD19 phosphorylation
being reduced upon disrupting the actin cytoskeleton (*Keppler et al., 2015*), we found that inhibiting
the Arp2/3 complex resulted in decreased CD19 phosphorylation, as well as reduced overlap
between BCR-Ag clusters and pCD19 clusters, at 3 min after the initiating B cell-APC contact. By 5
min, the differences between CK-666-treated B cells and control cells were smaller. Hence, inhibiting
the Arp2/3 complex reduces and delays initial Ag-induced BCR-CD19 interactions. Initial BCR-CD19
interactions are dependent on the immobilization of CD19 by the tetraspanin network (*Mattila*
et al., 2013). We found that inhibiting Arp2/3 complex-dependent actin polymerization increased
the lateral mobility of CD19 within the plasma membrane, suggesting that branched actin structures
also restrain its mobility. This increased mobility of CD19 may decrease the initial rate at which
productive BCR-CD19 collisions occur.

Although inhibiting the Arp2/3 complex significantly reduced proximal BCR signaling during the
first 5 min of B cell-APC encounter, a key question was whether this would translate into decreased
B cell activation. Indeed, CK-666 treatment reduced the ability of Ag-bearing APCs to stimulate a
transcriptional response at 3 hr, activation marker upregulation at 18 hr, and B cell proliferation
at 72 hr. Importantly, we found that adding CK-666 to B cells shortly after they had engaged
APCs did not impair the upregulation of B cell activation markers. As well, we found that Arp2/3
complex activity was not required for the upregulation of activation markers in response to PMA
plus ionomycin, stimuli that bypass the BCR but initiate many of the same downstream signaling
reactions. Taken together, these findings support the idea that Arp2/3 complex-dependent effects
on BCR-Ag microclusters that occur within the first few minutes of B cell-APC interactions amplify
initial BCR signaling reactions that are translated into B cell responses that occur up to 3 days later.

Consistent with our findings that Arp2/3 complex activity regulates both tonic BCR signaling and
APC-induced B cell activation, upstream activators of the Arp2/3 complex are important regulators
of B cell activation. Murine B cells lacking WASp, an NPF that activates the Arp2/3 complex, exhibit
reduced cell spreading, BCR-Ag microcluster formation, and BCR-induced tyrosine phosphorylation
in response to Ag-bearing lipid bilayers (*Liu et al., 2011*). The WASp-interacting protein WIP regulates
the activity and subcellular distribution of WASp, and also stabilizes existing actin filaments. Murine
B cells lacking WIP have defective CD19-mediated PI3K signaling and antibody responses (*Keppler*
et al., 2015). WASp activation is regulated by the Cdc42 GTPase and B cell-specific loss of Cdc42

results in aberrant actin organization, diminished BCR signaling, and a severe impairment in
antibody production (*Burbage et al., 2015*).
In line with its central role in many aspects of B cell function, human mutations that impair the
activation Arp2/3 complex result in disease. Mutations in WASp or WIP result in Wiskott-Aldrich
syndrome, an X-linked immunodeficiency disorder (*Candotti, 2018*). Similarly, missense mutations
in the *ARPC1B* gene have recently been described as causing a Wiskott-Aldrich syndrome-like disease
(*Kahr et al., 2017*). Although Wiskott-Aldrich syndrome is associated with increased susceptibility to
infections, many patients also develop autoimmunity and B-cell malignancies (*Candotti, 2018*). Our
finding that the loss of Arp2/3 complex activity in B cells results in increased tonic BCR signaling but
impaired APC-induced B cell activation may help explain this paradox.

Materials and Methods

Key Resources Table				
Reagent type	**Designation**	**Source or reference**	**Identifiers**	**Additional information**
siRNA	ON-TARGETplus Non-Targeting Pool,	Dharmacon	#D-001810-01-05	
siRNA	SMARTpool ON-TARGETplus, Dharmacon,	Dharmacon	#L-046642-01-0005	
Medium	RPMI-1640 without phenol red	Life Technologies	#32404014	
antibody	Goat anti-mouse IgG	Jackson Im-munoResearch	#115-005-008	Coverslip coating 2.5 µg/cm2
antibody	Goat anti-mouse IgM	Jackson Im-munoResearch	#115-005-020	Coverslip coating 2.5 µg/cm2
antibody	Rabbit anti-pZap70(Y319)/pSyk(Y352)	Cell Signaling Technologies	#2701	Immunofluorescence 1:200
antibody	Rabbit anti-pCD79a(Y182)	Cell Signaling Technologies	#5173	Immunofluorescence 1:400, Western blot 1:1000
antibody	Rabbit anti-CD79a	PMID: 1707541		Western blot 1:5000
antibody	Rabbit anti-pCD19(Y531)	Cell Signaling Technologies	#3571	Immunofluorescence 1:200, Western blot 1:1000
antiboday	Rabbit anti-CD19	Cell Signaling Technologies	#3574	Western blot 1:1000
antibody	Alexa Fluor 488 goat anti-rabbit IgG	Invitrogen	#A-11008	Immunofluorescence 1:400
antibody	Alexa Fluor 647 goat anti-rat IgG	Invitrogen	#A-21247	Immunofluorescence 1:400
antibody	Goat anti-Igκ	Southern Biotech	#1050-01	Stimulation 20 µg/ml
antibody	Rabbit anti-ACTR3 (Arp3)	Santa Cruz	#sc-15390	Western blot 1:1000
antibody	Rabbit anti-Arp2	Abcam	#ab128934	Western blot 1:1000
antibody	Mouse anti-β-actin	Santa Cruz	#sc-47778	Western blot 1:5000
antibody	Rabbit anti-p34-Arc/ARPC2	Millipore	#07-227	Western blot 1:1000
antibody	Rabbit anti-pERK	Cell Signaling Technologies	#9101	Western blot 1:1000
antibody	Rabbit anti-ERK	Cell Signaling Technologies	#9102	Western blot 1:1000

Reagent type	Designation	Source or reference	Identifiers	Additional information
antibody	Rabbit anti-pAkt	Cell Signaling Technologies	#9271	Western blot 1:1000
antibody	Rabbit anti-Akt	Cell Signaling Technologies	#9272	Western blot 1:1000
antibody	Goat anti-rabbit IgG(H+L)-HRP conjugate	Bio-Rad	#170-6515	Western blot 1:3000
antibody	Goat anti-mouse IgM Fab fragment-Cy3-conjugated	Jackson Im-munoResearch	#115-167-020	Single particle tracking 1 ng/ml
antibody	Rat anti-mouse IgD Fab fragment-Cy3-conjugated	ATCC	#HB-250 (11-26c)	Fab made by AbLab; SPT 100 ng/ml
antibody	Rat anti-mouse CD19 Fab fragment-Cy3-conjugated	ATCC	#HB-305 (1D3)	Fab made by AbLab; SPT 10 ng/ml
antibody	Rabbit anti-MHC II monoclonal antibody (M5/114)	Millipore	#MABF33	Coverslip coating 0.25 µg/cm2
antibody	2.4G2 monoclonal antibody	ATCC	#HB-197	0.25 µg/ml
antibody	Anti-CD69-FITC	eBioscience	#11-0691-82	Flow cytometry 1:200
antibody	Anti-CD86-APC	eBioscience	#17-0862-82	Flow cytometry 1:200
biological sample (bovine)	Fibronectin	Sigma-Aldrich	#F4759	Coverslip coating 5 µg/ml
Cell line (C. aethiops)	COS-7	American Type Culture Collection	#CRL-1651	
Cell line (M. musculus)	A20	American Type Culture Collection	#TIB-208	
Cell line (M. musculus)	A20 D1.3	PMID:9655489		F. Batista (Ragon Institute, Cambridge, MA)
Cell line (M. musculus)	B16-F1	American Type Culture Collection	#CRL-6323	
chemical compound, drug	CK-666	Calbiochem	#CAS 442633-00-3	100 µM
chemical compound, drug	CK-689	Calbiochem	#CAS 170930-46-8	100 µM
chemical compound, drug	(S)-nitro-blebbistatin (pnBB)	Cayman Chemicals	#CAS 856925-71-8	50 µM
chemical compound, drug	HaloTag Janelia Fluor 549 ligand	Promega	#GA1110	Cell labeling 1:2000
chemical compound, drug	HaloTag tetramethylrhodamine ligand	Promega	#G8251	Cell labeling 1:2000
chemical compound, drug	Rhodamine phalloidin	Thermo Fisher	#R415	Immunofluorescence 1:1000
chemical compound, drug	Alexa Fluor 568-conjugated phalloidin	Thermo Fisher	#A12380	Immunofluorescence 1:1000

Reagent type	Designation	Source or reference	Identifiers	Additional information
chemical compound, drug	Alexa Fluor 532-conjugated-phalloidin	Thermo Fisher	#A22282	Immunofluorescence 1:1000
chemical compound, drug	ProLong Diamond anti-fade reagent	Thermo Fisher	#P36965	
chemical compound, drug	ECL detection reagent	GE Life Sciences	#RPN2106	
chemical compound, drug	CFSE	Invitrogen	#C1157	Flow cytometry 2 μM
chemical compound, drug	7-AAD	Thermo Fisher	#A1310	Flow cytometry 1:1000
commercial assay or kit	B cell isolation kit	Stemcell Technologies	#19854A	
commercial assay or kit	AMAXA nucleofector kit V	Lonza	#VCA-1003	
commercial assay or kit	Ingenio electroporation solution	Mirus	#MIR 50117	
commercial assay or kit	Lipofectamine 3000	Thermo-Fisher	#L3000008	
commercial assay or kit	Fab preparation kit	Pierce	#44985	
Genetic reagent (M. musculus)	C57BL/6J	Jackson Laboratories	Stock #000664; MGI:3028467	
Genetic reagent (M. musculus)	C57BL/6-Tg(IghelMD4)4Ccg/J	Jackson Laboratories	Stock #002595; MGI:2384162	PMID:3261841
Genetic reagent (M. musculus)	C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog	PMID:21606508	MGI:5007644	PMID:21606508; K. Hogquist (University of Minnesota)
peptide, recombinant protein	BAFF	R&D Systems	#8876-BF-010	5 ng/ml
peptide, recombinant protein	IL-4	R&D Systems	#404-ML-010	5 ng/ml
recombinant DNA reagent	F-tractin-GFP	PMID:19846664		
recombinant DNA reagent	Myosin IIA-GFP	Addgene	#38297	
recombinant DNA reagent	mHEL-GFP	PMID:11373683		F. Batista (Ragon Institute, Cambridge, MA)
recombinant DNA reagent	mHEL-HaloTag	PMID: 29388105		M. Gold (University of British Columbia)
recombinant DNA reagent	Single-chain anti-Igκ antibody	PMID: 15738053		D. Nemazee (Scripps Reseach Institute)
recombinant DNA reagent	β-Actin–GFP			R. Nabi (University of British Columbia)
software, algorithm	ISIM deconvolution	PMID: 26210400		

Reagent type	Designation	Source or reference	Identifiers	Additional information
software, algorithm	Softworx	Applided Precision Ltd.; GE Healthcare Life Sciences		
software, algorithm	FIJI	PMID: 22743772		https://imagej.net/Fiji
software, algorithm	MATLAB	MathWorks	R2015b	
software, algorithm	MetaMorph	Molecular Devices		
software, algorithm	ICY	PMID: 22743774		http://icy.bioimageanalysis.org
software, algorithm	FlowJo	Tree Star	v10.5.3	
software, algorithm	Robust Regression and Outlier Removal (ROUT)	Graphad	v7	PMID 16526949

B cells

Spleens were obtained from 8- to 12-week old C57BL/6J (Jackson Laboratories, #000664), Nur77[GFP]
(*Moran et al., 2011*), or MD4 (*Goodnow et al., 1988*) (Jackson Laboratories, #002595) mice of either
sex following protocols approved by the University of British Columbia Animal Care Committee. B
cells were isolated using a negative selection B cell isolation kit (Stemcell Technologies, #19854A).
The A20 murine IgG[+] B-cell line was obtained from ATCC (#TIB-208). A20 D1.3 B cells expressing a
transgenic HEL-specific BCR were a gift from F. Batista (Ragon Institute, Cambridge, MA) (*Batista*
and Neuberger, 1998). A20 B cells were cultured in RMPI-1640 supplemented with 5% fetal calf
serum (FCS), 2 mM glutamine, 1 mM pyruvate, 50 μM 2-mercaptoethanol, 50 U/ml penicillin, and 50
μg/ml streptomycin (complete medium). A20 and A20 D1.3 B cells (3 x 10^6 cells) were transiently
transfected using the AMAXA nucleofector kit V (Lonza, #VCA-1003) or the Ingenio electroporation
kit (Mirus, #MIR 50117) with 1.5 μg of either control siRNA (ON-TARGETplus Non-Targeting Pool,
Dharmacon, #D-001810-01-05) or Actr3 siRNA (SMARTpool ON-TARGETplus, Dharmacon, #L-046642-
01-0005), or with 2 μg of plasmid DNA encoding either F-tractin-GFP (*Johnson and Schell, 2009*) or
myosin IIA-GFP (Addgene, #38297) (*Jacobelli et al., 2009*). Transfected cells were cultured for 24
hr before use. Where indicated, B cells (7.5 x 10^5 cells/ml) were pre-treated with 100 μM of the
Arp2/3 complex inhibitor CK-666 (Calbiochem, #CAS 442633-00-3) or the inactive analog CK-689
(Calbiochem, #CAS 170930-46-8) (*Hetrick et al., 2013*) for 1 hr at 37°C or with 50 μM of the myosin
IIA inhibitor pnBB (Cayman Chemicals, #CAS 856925-71-8) or DMSO for 30 min at 37°C
658

APCs

APCs were generated as described previously (*Freeman et al., 2011*; *Wang et al., 2017*, *2018*). Briefly,
COS-7 cells (ATCC, #CRL-1651) or B16F1 cells (ATCC, #CRL-6323) were transiently transfected using
Lipofectamine 3000 (Thermo Fisher, #L3000008) with plasmid DNA encoding either mHEL-GFP,
mHEL-HaloTag, or a single-chain anti-Igκ antibody. mHEL-GFP is a transmembrane protein consist-
ing of the complete HEL and GFP proteins in the extracellular domain, fused to the transmembrane
region and cytosolic domain of the H-2K^b protein (*Batista et al., 2001*). mHEL-HaloTag consists of
the complete HEL protein fused to the transmembrane region and cytosolic domain of H-2K^b, with
the the HaloTag protein fused to the C-terminus (see *Figure 1*) (*Wang et al., 2018*). The single-chain
anti-Igκ antibody is a transmembrane protein consisting of the single-chain Fv with the variable
regions from the 187.1 rat anti-Igκ monocolonal antibody, fused to the hinge and membrane-

proximal domains of rat IgG1 and the transmembrane and cytoplasmic domains of the H-2K^d
protein (*Ait-Azzouzene et al., 2005*). Where indicated, B16F1 cells were cotransfected with 1.5 µg of
either control siRNA (ON-TARGETplus Non-Targeting Pool, Dharmacon, #D-001810-01-05) or Actr3
siRNA (SMARTpool ON-TARGETplus, Dharmacon, #L-046642-01-0005). The transfected cells were
cultured in DMEM supplemented with 5% FCS, 2 mM glutamine, 1 mM pyruvate, 50 U/ml penicillin,
and 50 µg/ml streptomycin for 24 hr before being used for experiments.

Fluorescence recovery after photobleaching

COS-7 cells that had been transfected with actin-GFP (1.5 x 10^5 cells) were plated onto fibronectin-
coated coverslips and cultured overnight. Fluorescence recovery after photobleaching was per-
formed as described previously (*Freeman et al., 2011*) using an Olympus FV1000 confocal micro-
scope with a 100× NA 1.40 oil objective. Briefly, within a selected region of interest (ROI), the
pre-bleached fluorescence intensity was measured, followed by photobleaching using the 405 nm
laser (100% intensity for 3 s). Fluorescence recovery within the same ROI was then recorded for 40
s. FluoView v4.0 (Olympus) software was used to quantify the fluorescence within the ROI, which
was then normalized to the pre-bleach fluorescence intensity.

BCR microcluster dynamics

Live cell imaging of BCR-Ag microcluster dynamics was performed as described previously (*Wang
et al., 2018*). mHEL-GFP-expressing COS-7 cells were plated onto fibronectin-coated coverslips and
cultured overnight. The coverslip was then washed with modified HEPES-buffered saline (mHBS;
25 mM HEPES, pH 7.2, 125 mM NaCl, 5 mM KCl, 1 mM CaCl$_2$, 1 mM Na$_2$HPO$_4$, 0.5 mM MgSO$_4$, 1
mg/ml glucose, 2 mM glutamine, 1 mM pyruvate, 50 µM 2-mercaptoethanol) supplemented with
2% FCS (imaging medium) and mounted onto the microscope in a 37°C imaging chamber. A20
D1.3 B cells were pre-treated with CK-689 or CK-666 for 1 hr in imaging medium. The B cells (5 x
10^5 in 0.1 ml) were then added to the COS-7 APCs and imaging was started immediately. Imaging
was performed using a spinning disk confocal microscope system (Intelligent Imaging Innovations)
consisting of a Zeiss Axiovert 200M microscope with a 100× NA 1.45 oil Pan-Fluor objective and a
QuantEM 512SC Photometrics camera. Z-stacks with 0.2-µm optical z-slices through the B cell-APC
contact site were acquired at 12 s intervals. Alternatively, F-tractin-GFP-expressing A20 D1.3 B cells
were pre-treated with CK-689 or CK-666, added to mHEL-HaloTag-expressing COS-7 cell APCs that
had been labeled with the Janelia Fluor 549 dye (*Grimm et al., 2015*), and imaged using 3D-ISIM
(*York et al., 2013*). Z-stacks through the B cell-APC contact site were acquired every 6.6 s and the
images were deconvolved as described (*York et al., 2013*). Briefly, the images were subjected to 10
iterations of Richardson-Lucy deconvolution with a Gaussian point spread function having a full
width half maximum (0.22 µm lateral and 0.5 µm axial) that was derived from measurements of
100 nm yellow/green beads. Within a single experiment, all images were acquired using identical
settings. FIJI software (*Schindelin et al., 2012*) was used to quantify cell area, generate kymographs,
quantify the fluorescence intensity of Ag in microclusters, and determine microcluster size. Custom
FIJI macros were used and are available at https://github.com/madscience12/FIJImacros

Actin organization and dynamics in B cells spreading on anti-Ig coated coverslips

Glass coverslips were coated with 2.5 µg/cm^2 goat anti-mouse IgG (for A20 B cells; Jackson Im-
munoResearch, #115-005-008) or goat anti-mouse IgM (for primary B cells; Jackson ImmunoRe-
search, #115-005-020) as described (*Lin et al., 2008*). B cells were pre-treated for 1 hr with CK-666
or CK-689 before adding 7.5 x 10^4 cells in 0.1 ml imaging medium to the coverslips. Cells were
fixed and permeabilized as described below for immunostaining. F-actin was visualized using
rhodamine- or Alexa Fluor 568-conjugated phalloidin (Thermo Fisher, #R415, #A12380, respectively;
1:1000). For live cell imaging at 37°C, F-tractin-GFP-expressing A20 B cells were imaged using either
a Zeiss LSM 880 Airyscan microscope in super-resolution mode with a 63× 1.4 NA objective or
a TIRF-SIM microscope (DeltaVision OMX-SR, GE Healthcare Life Sciences) equipped with a 60×

1.42 NA objective (Olympus). For Airyscan images, raw data were processed using automatically determined parameters. For TIRF-SIM images, raw data were reconstructed using Softworx (Applied Precision Ltd.; GE Healthcare Life Sciences) and with a value of 0.01 for the Wiener filter constant. Alternatively, the cells were fixed at the indicated times with 4% paraformaldehyde (PFA), permeabilized, and stained for F-actin as described below. FIJI software (*Schindelin et al., 2012*) was used to quantify cell area and generate kymographs.

STED Microscopy

STED microscopy was performed as described previously (*Wang et al., 2018*). Briefly, 5 x 10^4 A20 B cells in 0.1 ml imaging medium were allowed to spread on anti-IgG-coated coverslips before being fixed and stained with Alexa Fluor 532-conjugated-phalloidin (Thermo Fisher, #A22282). STED images were acquired using a Leica TCS SP8 laser scanning STED system equipped with a 592 nm depletion laser, a CX PL APO 100× NA 1.40 oil objective, and a Leica HyD high sensitivity detector. Image deconvolution was performed using Huygens software (Scientific Volume Imaging, Hilversum, Netherlands).

Analysis of APC-induced BCR signaling by immunostaining

Primary murine B cells (10^5 in 0.1 ml imaging medium) from C57BL/6J or MD4 mice that had been pre-treated with CK-689,CK-666 were added to COS-7 APCs expressing either the single-chain anti-Igκ surrogate Ag or mHEL-HaloTag that was labeled with HaloTag tetramethylrhodamine ligand (Promega, #G8251). After the indicated times at 37°C, the cells were fixed with 4% PFA for 10 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 in PBS for 3 min and blocked with 2% BSA in PBS for 30 min, both at room temperature. Primary antibodies that were diluted in blocking buffer (2% BSA in PBS) were added for 1 hr at room temperature, or overnight at 4°C for anti-pCD79. The primary antibodies, all from Cell Signaling Technologies, were: pZap70(Y319)/pSyk(Y352) (#2701; 1:200), pCD79a(Y182) (#5173; 1:400), and pCD19(Y531) (#3571; 1:200). The coverslips were then incubated for 30 min at room temperature with a mixture of Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, #A-11008; 1:400) secondary antibody, fluorophore-conjugated phalloidin to visualize F-actin, and Alexa Fluor 647 goat anti-rat IgG (Invitrogen, #A-21247; 1:400) to detect the rat IgG1 portion of the surrogate Ag and thereby visualize Ag clusters. Coverslips were mounted onto slides using ProLong Diamond anti-fade reagent (Thermo Fisher, #P36965).

Quantification of cluster-associated fluorescence and overlap

The total fluorescence intensity of clustered Ag or clustered signaling molecules at the B cell-APC interface was quantified as follows using custom MATLAB code. Each image was filtered (i.e. convolved) with a 3×3 averaging filter to smooth noise. Then, the standard deviation of the background pixel intensities in the filtered image was estimated to be $\sigma = 1.4826 \times \mathrm{MAD}(F_{3\times3}(I))$, where $\mathrm{MAD}(F_{3\times3}(I))$ is the median absolute deviation of the pixel intensities in the filtered image, $F_{3\times3}(I)$. A binary mask (Mask 1) was then defined by thresholding the pixel intensities in the filtered image at $N\sigma$ above the median intensity, where $N = 2$ for pCD79, 2 for pSyk, or 3 for pCD19 experiments.

Next, the original, unfiltered image I was filtered with Laplacian of Gaussian (LoG) filters of different widths h. Each LoG filter highlights fluorescent spots and edges of fluorescent features at a specific scale determined by h. Regions of approximately uniform pixel intensities become approximately zero after filtering with a LoG filter of width h that is substantially smaller than the size of the uniform-intensity region. For each LoG-filtered image, $\mathrm{LoG}_h(I)$, the standard deviation σ_h of the background pixel values was again estimated as described above, i.e. $\sigma_h = 1.4826 \times \mathrm{MAD}(\mathrm{LoG}_h(I))$. A second binary mask (Mask 2) was then defined by identifying pixels that exceeded a threshold $N\sigma_h$ in $\mathrm{LoG}_h(I)$ at any scale, where $N = 3$ for pCD79, 5 for pSyk, or 4 for pCD19 experiments. Additionally, any pixel that passed this threshold was removed from the mask if its greatest negative response to the different LoG filters was greater than its maximum positive response. This last step helps

to sharpen the edges of fluorescent features that could have been excessively blurred by filters of large width. A final binary mask was defined by taking the intersection of Mask 1 and Mask 2. Hence, pixels were retained in the final mask if and only if they were present in both Mask 1 and Mask 2.

To quantify fluorescence in an image, background fluorescence was estimated by calculating the median intensity of the pixels outside of the mask, and this was subsequently subtracted from the whole image. Next, the intensities of pixels outside of the mask were set to 0 to leave only those pixels that were present in the mask. Finally, these pixel intensities were summed to obtain the total fluorescence intensity in the image. For each B cell, the total fluorescence intensity derived in this manner for a given signaling molecule was normalized to the total fluorescence intensity of clustered Ag on the same B cell. To quantify overlap we used custom MATLAB code to calculate Manders' coefficients (*Manders et al., 1993*) after processing the images as described above to subtract background fluorescence and extract fluorescent features defined by the mask. All MATLAB scripts are available at https://bitbucket.org/jscurll/bolger-munro_image_analysis_scripts/src/32434bd6725397459af901000afddab7bd9b58a2?at=master

Analysis of BCR signaling by immunoblotting

After being pre-treated for 1 hr with CK-666 or CK-689, 4×10^6 primary B cells in 0.1 ml imaging medium were added to anti-Igκ-expressing COS-7 cells. Alternatively, 4×10^6 primary B cells in 0.1 ml of imaging medium were stimulated with 20 µg/ml soluble goat anti-Igκ antibodies (Southern Biotech, #1050-01). Cells were lysed in RIPA buffer (30 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Igepal (Sigma-Aldrich), 0.5% sodium deoxycholate, 0.1% SDS, 2 mM EDTA, 1mM PMSF, 10 µg/ml leupeptin, 1 µg/ml aprotinin, 25 mM β-glycerophosphate, 1 µg/ml pepstatin A, 10 µg/ml soybean trypsin inhibitor, 1 mM Na_3MoO_4, 1mM Na_3VO_4) and analyzed by immunoblotting. Filters were incubated overnight at 4°C with antibodies against Arp3 (Santa Cruz, #sc-15390; 1:1000), Arp2 (abcam, #ab128934; 1:1000), p34 (Millipore, #07-227; 1:1000), actin (Santa Cruz, #sc-47778; 1:5000), or CD79a ((*Gold et al., 1991*); 1:5000), or with the following antibodies from Cell Signaling Technologies: pCD79a (#5173; 1:1000); pCD19 (#3571; 1:1000); CD19 (#3574; 1:1000); pERK (#9101; 1:1000), ERK (#9102; 1:1000), pAkt (#9271; 1:1000), or Akt (#9272; 1:1000). Immunoreactive bands were visualized using horseradish peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad #170-6515; 1:3000), followed by ECL detection (GE Life Sciences). Blots were quantified and imaged using a Li-Cor C-DiGit imaging system. *Figure 9-Figure Supplement 6* shows complete images of blots from which sections are shown in *Figure 6*, *Figure 7*, and *Figure 8*.

Single-particle tracking (SPT)

SPT using directly-conjugated Fab fragments of antibodies was performed as described previously (*Abraham et al., 2017*). Primary B cells from C57BL/6J mice were resuspended to 10^7 cell/ml in RPMI-1640 without phenol red (Life Technologies #32404014) plus 5 mM HEPES. CK-666 or CK-689 was added to a final concentration of 100 µM and the cells were incubated for 1 hr at 37°C. The cells were then placed on ice and labeled for 5 min with 1 ng/ml Cy3-conjugated anti-mouse IgM Fab fragments (Jackson ImmunoResearch, #115-167-020), 100 ng/ml Cy3-conjugated Fab fragments from the 11-26c rat anti-mouse IgD monoclonal antibody (ATCC, #HB-250), or 10 ng/ml Cy3-conjugated Fab fragments of the 1D3 rat anti-mouse CD19 monoclonal antibody (ATCC, #HB-305). Fab fragments of the 11-26c antibody and 1D3 antibody were prepared by AbLab (Vancouver, Canada) using a Fab preparation kit (Pierce, #44985). The labeled B cells were then attached to coverslips that had been coated with 0.25 µg/cm^2 of the non-stimulatory M5/114 anti-MHC II monoclonal antibody (Millipore, #MABF33). SPT was carried out at 37°C using an Olympus total internal reflection fluorescence microscopy (TIRFM) system consisting of an inverted microscope (Olympus IX81) equipped with a 150× NA 1.45 TIRFM objective (Olympus), motorized filter wheel (Olympus), high performance electorn multiplier (EM)-charge-coupled device (CCD) camera (Photometrics Evolve), and real-time data acquisition software (Metamorph). The 561 nm solid-state diode laser was used to excite

Cy3-labeled samples. The TIRF plane was adjusted to yield a penetration depth of 85-90 nm from the coverslip and the cells were imaged for 10 s at 33 Hz.

Single particles were detected and tracked using Icy bioimaging analysis software (*de Chaumont et al., 2012*) with the UnDecimated Wavelet Transform Detector plug-in and the Multiple Hypothesis Spot-Tracking plug-in (*Chenouard et al., 2013*, *2014*). Diffusion coefficients and confinement diameters were determined as described previously (*Abraham et al., 2017*). The diffusion model assumes that displacements arise from a two-dimensional Brownian diffusion process. Diffusion coefficients were calculated for individual tracks using a maximum likelihood estimation approach that accounts for noise due to positional errors in acquisition as well as blurring during acquisition (*Berglund, 2010*).

APC-induced expression of the Nur77-GFP reporter gene, CD69, and CD86

COS-7 APCs expressing the anti-Igκ surrogate Ag (2 x 10^5 cells per well) were cultured overnight in 12-well plates. Primary B cells from C57BL/6J mice or Nur77^{GFP} mice were incubated in complete medium with 100 µM CK-666 or CK-689 for 1 hr and then 10^6 B cells were added to each well containing APCs. After co-culturing the cells for 18 hr, the B cells and APCs were removed from the wells by pipetting. GFP levels were quantified by flow cytometry. To quantify cell surface expression of CD69 or CD86, the cells were resuspended in ice-cold FACS buffer (PBS with 2% FCS), Fc receptors were blocked by adding 25 µg/ml of the 2.4G2 monoclonal antibody (ATCC, #HB-197) for 5 min, and then the cells were stained for 30 min at 4°C with anti-CD69-FITC (eBioscience, #11-0691-82 1:200), anti-CD86-APC (eBioscience, #17-0862-82; 1:200), and DAPI (1:10000) for 30 min. Fluorescence was quantified using an LSR II cytometer (Becton Dickinson) and the data were analyzed using FlowJo software (Treestar). Forward and side scatter, together with DAPI staining, were used to gate on single live (GFP-positive or DAPI-negative) B cells. The Ag-induced increase in fluorescence was calculated as the geometric mean for B cells cultured with anti-Igκ-expressing APCs, minus the geometric mean for B cells cultured with parental COS-7 cells that do not express the surrogate Ag. The gating strategies and sample calculations are shown in *Figure 9-Figure Supplement 1* (GFP expression) and *Figure 9-Figure Supplement 2* (CD69, CD86).

CFSE proliferation and cell death assays

COS-7 APCs expressing the anti-Igκ surrogate Ag (2 x 10^5 cells per well) were cultured overnight in 12-well plates. Primary B cells from C57BL/6J mice were resuspended in complete medium and labeled with 2 µM CFSE (Invitrogen, #C1157) for 8 min prior to being treated with CK-666 or CK-689 for 1 hr. The B cells were then added to the APCs and cultured in complete medium with 5 ng/ml BAFF (R&D Systems, #8876-BF-010) and 5 ng/ml IL-4 (R&D Systems, #404-ML-010). After 24-72 hr the cells were resuspended by pipetting, stained with 7-AAD (Thermo Fisher, #A1310; 1:1000) to identify dead cells, and analyzed by flow cytometry using an LSR II flow cytometer. Forward and side scatter were used to gate on single B cells. CFSE fluorescence in live (7-AAD-negative) B cells was then quantified. FlowJo software was used to analyze the data.

Statistical Analysis

Two-tailed paired t-tests were used to compare mean values for matched sets of samples. The Mann-Whitney U test was used to compare ranks in samples with many cells and high variability (e.g. dot plots for immunofluorescence signaling data). For signaling experiments, outliers were identified using Robust Regression and Outlier Removal (ROUT) in GraphPad Prism with Q set to 1% (*Motulsky and Brown, 2006*). Kolmogorov-Smirnov tests were used to compare SPT cumulative frequency distributions and FRAP curves.

Acknowledgments

We thank the UBC Life Sciences Institute Imaging Facility, the UBC Flow Cytometry Facility, Harshad Vishwasrao and Hari Shroff from the NIH Advanced Imaging and Microscopy (AIM) Resource, Linda

Matsuuchi and Jia Wang for feedback on the manuscript, and Connor Morgan-Lang for help with data visualization.

Funding

This work was supported by grants MOP-68865 and PJT-152946 (to M.R.G) from the Canadian Institutes of Health Research and by a Natural Science and Engineering Research Council (NSERC) Discovery Grant (RGPIN-2015-04611) to D.C. M.B.-M. was supported by a doctoral scholarship from the University of British Columbia.

Competing interests

The authors declare that no competing interests exist.

References

Abraham L, Lu HY, Falcão RC, Scurll J, Jou T, Irwin B, Tafteh R, Gold MR, Coombs D. Limitations of Qdot labelling compared to directly-conjugated probes for single particle tracking of B cell receptor mobility. Scientific Reports. 2017 dec; 7(1):11379. http://www.nature.com/articles/s41598-017-11563-9, doi: 10.1038/s41598-017-11563-9.

Abraham L, Wang JC, Bolger-Munro M, Gold MR. Structure, Function, and Spatial Organization of the B Cell Receptor. In: Michael J H Ratcliffe, editor. *Encyclopedia of Immunobiology* Academic Press; 2016.p. 40–54. http://linkinghub.elsevier.com/retrieve/pii/B9780123742797050050, doi: doi.org/10.1016/B978-0-12-374279-7.05005-0.

Ait-Azzouzene D, Verkoczy L, Peters J, Gavin A, Skog P, Vela JL, Nemazee D. An immunoglobulin Cκ-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. The Journal of Experimental Medicine. 2005 mar; 201(5):817–828. http://www.ncbi.nlm.nih.gov/pubmed/15738053, doi: 10.1084/jem.20041854.

Babich A, Li S, O'Connor RS, Milone MC, Freedman BD, Burkhardt JK. F-actin polymerization and retrograde flow drive sustained PLCγ1 signaling during T cell activation. The Journal of Cell Biology. 2012 jun; 197(6):775–787. http://www.jcb.org/lookup/doi/10.1083/jcb.201201018, doi: 10.1083/jcb.201201018.

Basu R, Huse M. Mechanical Communication at the Immunological Synapse. Trends in cell biology. 2017; 27(4):241–254. http://www.ncbi.nlm.nih.gov/pubmed/27986534, doi: 10.1016/j.tcb.2016.10.005.

Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nature Reviews Immunology. 2009 jan; 9(1):15–27. http://www.nature.com/doifinder/10.1038/nri2454, doi: 10.1038/nri2454.

Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature. 2001 may; 411(6836):489–494. http://www.nature.com/articles/35078099, doi: 10.1038/35078099.

Batista FD, Neuberger MS. Affinity Dependence of the B Cell Response to Antigen: A Threshold, a Ceiling, and the Importance of Off-Rate. Immunity. 1998 jun; 8(6):751–759. http://linkinghub.elsevier.com/retrieve/pii/S1074761300805804, doi: 10.1016/S1074-7613(00)80580-4.

Berglund AJ. Statistics of camera-based single-particle tracking. Physical Review E. 2010 jul; 82(1):011917. https://link.aps.org/doi/10.1103/PhysRevE.82.011917, doi: 10.1103/PhysRevE.82.011917.

Bezanilla M, Gladfelter AS, Kovar DR, Lee WL. Cytoskeletal dynamics: A view from the membrane. The Journal of Cell Biology. 2015 may; 209(3):329–337. http://www.jcb.org/lookup/doi/10.1083/jcb.201502062, doi: 10.1083/jcb.201502062.

Buhl AM, Pleiman CM, Rickert RC, Cambier JC. Qualitative Regulation of B Cell Antigen Receptor Signaling by CD19: Selective Requirement for PI3-Kinase Activation, Inositol-1,4,5-Trisphosphate Production and Ca 2+ Mobilization. The Journal of Experimental Medicine. 1997 dec; 186(11):1897–1910. http://www.jem.org/lookup/doi/10.1084/jem.186.11.1897, doi: 10.1084/jem.186.11.1897.

Bunnell SC, Kapoor V, Trible RP, Zhang W, Samelson LE. Dynamic Actin Polymerization Drives T Cell Receptor–Induced Spreading. Immunity. 2001 mar; 14(3):315–329. http://www.ncbi.nlm.nih.gov/pubmed/11290340, doi: 10.1016/S1074-7613(01)00112-1.

Burbage M, Keppler SJ, Gasparrini F, Martínez-Martín N, Gaya M, Feest C, Domart MC, Brakebusch C, Collinson L, Bruckbauer A, Batista FD. Cdc42 is a key regulator of B cell differentiation and is required for antiviral humoral immunity. The Journal of Experimental Medicine. 2015 jan; 212(1):53–72. http://www.jem.org/lookup/doi/10.1084/jem.20141143, doi: 10.1084/jem.20141143.

Candotti F. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. Journal of Clinical Immunology. 2018 jan; 38(1):13–27. http://link.springer.com/10.1007/s10875-017-0453-z, doi: 10.1007/s10875-017-0453-z.

de Chaumont F, Dallongeville S, Chenouard N, Hervé N, Pop S, Provoost T, Meas-Yedid V, Pankajakshan P, Lecomte T, Le Montagner Y, Lagache T, Dufour A, Olivo-Marin JC. Icy: an open bioimage informatics platform for extended reproducible research. Nature Methods. 2012 jul; 9(7):690–696. http://www.nature.com/articles/nmeth.2075, doi: 10.1038/nmeth.2075.

Chenouard N, Bloch I, Olivo-Marin JC. Multiple Hypothesis Tracking for Cluttered Biological Image Sequences. IEEE Transactions on Pattern Analysis and Machine Intelligence. 2013 nov; 35(11):2736–3750. http://www.ncbi.nlm.nih.gov/pubmed/23689865, doi: 10.1109/TPAMI.2013.97.

Chenouard N, Smal I, de Chaumont F, Maška M, Sbalzarini IF, Gong Y, Cardinale J, Carthel C, Coraluppi S, Winter M, Cohen AR, Godinez WJ, Rohr K, Kalaidzidis Y, Liang L, Duncan J, Shen H, Xu Y, Magnusson KEG, Jaldén J, et al. Objective comparison of particle tracking methods. Nature Methods. 2014 mar; 11(3):281–289. http://www.nature.com/articles/nmeth.2808, doi: 10.1038/nmeth.2808.

Chhabra ES, Higgs HN. The many faces of actin: matching assembly factors with cellular structures. Nature Cell Biology. 2007 oct; 9(10):1110–1121. http://www.nature.com/articles/ncb1007-1110, doi: 10.1038/ncb1007-1110.

Collins C, Denisin AK, Pruitt BL, Nelson WJ. Changes in E-cadherin rigidity sensing regulate cell adhesion. Proceedings of the National Academy of Sciences. 2017 jul; 114(29):E5835–E5844. http://www.pnas.org/lookup/doi/10.1073/pnas.1618676114, doi: 10.1073/pnas.1618676114.

Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Molecular immunology. 2004 jul; 41(6-7):599–613. http://linkinghub.elsevier.com/retrieve/pii/S0161589004001245, doi: 10.1016/j.molimm.2004.04.008.

DeFranco AL, Raveche ES, Paul WE. Separate control of B lymphocyte early activation and proliferation in response to anti-IgM antibodies. Journal of immunology (Baltimore, Md : 1950). 1985 jul; 135(1):87–94. http://www.jimmunol.org/content/135/1/87.

Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL, Tybulewicz VLJ, Batista FD. CD19 is essential for B cell activation by promoting B cell receptor–antigen microcluster formation in response to membrane-bound ligand. Nature Immunology. 2008 jan; 9(1):63–72. http://www.nature.com/articles/ni1547, doi: 10.1038/ni1547.

Dustin ML. Cell adhesion molecules and actin cytoskeleton at immune synapses and kinapses. Current Opinion in Cell Biology. 2007 oct; 19(5):529–533. http://linkinghub.elsevier.com/retrieve/pii/S0955067407001202, doi: 10.1016/j.ceb.2007.08.003.

Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nature Immunology. 2000 jul; 1(1):23–29. http://www.nature.com/articles/ni0700{_}23, doi: 10.1038/76877.

Dustin ML, Groves JT. Receptor Signaling Clusters in the Immune Synapse. Annual Review of Biophysics. 2012 jun; 41(1):543–556. http://www.annualreviews.org/doi/10.1146/annurev-biophys-042910-155238, doi: 10.1146/annurev-biophys-042910-155238.

Ennomani H, Letort G, Guérin C, Martiel JL, Cao W, Nédélec F, De La Cruz EM, Théry M, Blanchoin L. Architecture and Connectivity Govern Actin Network Contractility. Current Biology. 2016 mar; 26(5):616–626. https://linkinghub.elsevier.com/retrieve/pii/S0960982216000543, doi: 10.1016/j.cub.2015.12.069.

Fleire SJ. B Cell Ligand Discrimination Through a Spreading and Contraction Response. Science. 2006 may; 312(5774):738–741. http://www.sciencemag.org/cgi/doi/10.1126/science.1123940, doi: 10.1126/science.1123940.

Freeman SA, Jaumouillé V, Choi K, Hsu BE, Wong HS, Abraham L, Graves ML, Coombs D, Roskelley CD, Das R, Grinstein S, Gold MR. Toll-like receptor ligands sensitize B-cell receptor signalling by reducing actin-dependent spatial confinement of the receptor. Nature Communications. 2015 dec; 6(1):6168. http://www.nature.com/articles/ncomms7168, doi: 10.1038/ncomms7168.

Freeman SA, Lei V, Dang-Lawson M, Mizuno K, Roskelley CD, Gold MR. Cofilin-mediated F-actin severing is regulated by the Rap GTPase and controls the cytoskeletal dynamics that drive lymphocyte spreading and BCR microcluster formation. The Journal of Immunology. 2011 dec; 187(11):5887–5900. http://www.ncbi.nlm.nih.gov/pubmed/22068232, doi: 10.4049/jimmunol.1102233.

Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity. 2000; 13(1):47–57. doi: 10.1016/S1074-7613(00)00007-8.

Fujimoto M, Poe JC, Satterthwaite AB, Wahl MI, Witte ON, Tedder TF. Complementary Roles for CD19 and Bruton's Tyrosine Kinase in B Lymphocyte Signal Transduction. The Journal of Immunology. 2002 jun; 168(11):5465–5476. http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.168.11.5465, doi: 10.4049/jimmunol.168.11.5465.

Gasparrini F, Feest C, Bruckbauer A, Mattila PK, Mu ller J, Nitschke L, Bray D, Batista FD. Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling. The EMBO Journal. 2016 feb; 35(3):258–280. http://www.ncbi.nlm.nih.gov/pubmed/26671981, doi: 10.15252/embj.201593027.

Geahlen RL. Syk and pTyr'd: Signaling through the B cell antigen receptor. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2009 jul; 1793(7):1115–1127. http://linkinghub.elsevier.com/retrieve/pii/S0167488909000779, doi: 10.1016/j.bbamcr.2009.03.004.

Gold MR, Matsuuchi L, Kelly RB, DeFranco AL. Tyrosine phosphorylation of components of the B-cell antigen receptors following receptor crosslinking. Proceedings of the National Academy of Sciences. 1991 apr; 88(8):3436–3440. http://www.ncbi.nlm.nih.gov/pubmed/1707541, doi: 10.1073/pnas.88.8.3436.

Goley ED, Welch MD. The ARP2/3 complex: an actin nucleator comes of age. Nature Reviews Molecular Cell Biology. 2006 oct; 7(10):713–726. http://www.nature.com/articles/nrm2026, doi: 10.1038/nrm2026.

Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, Pritchard-Briscoe H, Wotherspoon JS, Loblay RH, Raphael K, Trent RJ, Basten A. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988 aug; 334(6184):676–682. http://www.nature.com/doifinder/10.1038/334676a0, doi: 10.1038/334676a0.

Grimm JB, English BP, Chen J, Slaughter JP, Zhang Z, Revyakin A, Patel R, Macklin JJ, Normanno D, Singer RH, Lionnet T, Lavis LD. A general method to improve fluorophores for live-cell and single-molecule microscopy. Nature Methods. 2015 mar; 12(3):244–250. http://www.ncbi.nlm.nih.gov/pubmed/25599551, doi: 10.1038/nmeth.3256.

Gupta N, Wollscheid B, Watts JD, Scheer B, Aebersold R, DeFranco AL. Quantitative proteomic analysis of B cell lipid rafts reveals that ezrin regulates antigen receptor–mediated lipid raft dynamics. Nature Immunology. 2006 jun; 7(6):625–633. http://www.nature.com/articles/ni1337, doi: 10.1038/ni1337.

Hammer JA, Burkhardt JK. Controversy and consensus regarding myosin II function at the immunological synapse. Current Opinion in Immunology. 2013 jun; 25(3):300–306. http://linkinghub.elsevier.com/retrieve/pii/S0952791513000630, doi: 10.1016/j.coi.2013.03.010.

Harwood NE, Batista FD. Early Events in B Cell Activation. Annual Review of Immunology. 2010 mar; 28(1):185–210. http://www.annualreviews.org/doi/10.1146/annurev-immunol-030409-101216, doi: 10.1146/annurev-immunol-030409-101216.

Harwood NE, Batista FD. The Cytoskeleton Coordinates the Early Events of B-cell Activation. Cold Spring Harbor Perspectives in Biology. 2011 feb; 3(2):a002360–a002360. http://cshperspectives.cshlp.org/lookup/doi/10.1101/cshperspect.a002360, doi: 10.1101/cshperspect.a002360.

Hashimoto-Tane A, Yokosuka T, Sakata-Sogawa K, Sakuma M, Ishihara C, Tokunaga M, Saito T. Dynein-Driven Transport of T Cell Receptor Microclusters Regulates Immune Synapse Formation and T Cell Activation. Immunity. 2011 jun; 34(6):919–931. http://linkinghub.elsevier.com/retrieve/pii/S1074761311002287, doi: 10.1016/j.immuni.2011.05.012.

Hetrick B, Han MS, Helgeson LA, Nolen BJ. Small Molecules CK-666 and CK-869 Inhibit Actin-Related Protein 2/3 Complex by Blocking an Activating Conformational Change. Chemistry & Biology. 2013 may; 20(5):701–712. http://www.ncbi.nlm.nih.gov/pubmed/23623350, doi: 10.1016/j.chembiol.2013.03.019.

Hoogeboom R, Natkanski EM, Nowosad CR, Malinova D, Menon RP, Casal A, Tolar P. Myosin IIa Promotes Antibody Responses by Regulating B Cell Activation, Acquisition of Antigen, and Proliferation. Cell Reports. 2018 may; 23(8):2342–2353. http://linkinghub.elsevier.com/retrieve/pii/S221112471830665X, doi: 10.1016/j.celrep.2018.04.087.

Ilani T, Vasiliver-Shamis G, Vardhana S, Bretscher A, Dustin ML. T cell antigen receptor signaling and immunological synapse stability require myosin IIA. Nature Immunology. 2009 may; 10(5):531–539. http://www.nature.com/articles/ni.1723, doi: 10.1038/ni.1723.

Jacobelli J, Bennett FC, Pandurangi P, Tooley AJ, Krummel MF. Myosin-IIA and ICAM-1 Regulate the Interchange between Two Distinct Modes of T Cell Migration. The Journal of Immunology. 2009 feb; 182(4):2041 LP – 2050. http://www.jimmunol.org/content/182/4/2041.abstract.

Jacobelli J, Chmura SA, Buxton DB, Davis MM, Krummel MF. A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nature Immunology. 2004 may; 5(5):531–538. http://www.nature.com/articles/ni1065, doi: 10.1038/ni1065.

Johnson HW, Schell MJ. Neuronal IP(3) 3-Kinase is an F-actin–bundling Protein: Role in Dendritic Targeting and Regulation of Spine Morphology. Molecular Biology of the Cell. 2009 dec; 20(24):5166–5180. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793293/, doi: 10.1091/mbc.E09-01-0083.

Kahr WHA, Pluthero FG, Elkadri A, Warner N, Drobac M, Chen CH, Lo RW, Li L, Li R, Li Q, Thoeni C, Pan J, Leung G, Lara-Corrales I, Murchie R, Cutz E, Laxer RM, Upton J, Roifman CM, Yeung RSM, et al. Loss of the Arp2/3 complex component ARPC1B causes platelet abnormalities and predisposes to inflammatory disease. Nature Communications. 2017; 8:14816. https://www.ncbi.nlm.nih.gov/pubmed/28368018, doi: 10.1038/ncomms14816.

Keppler SJ, Gasparrini F, Burbage M, Aggarwal S, Frederico B, Geha RS, Way M, Bruckbauer A, Batista FD. Wiskott-Aldrich Syndrome Interacting Protein Deficiency Uncovers the Role of the Co-receptor CD19 as a Generic Hub for PI3 Kinase Signaling in B Cells. Immunity. 2015 oct; 43(4):660–673. http://www.sciencedirect.com/science/article/pii/S1074761315003891, doi: 10.1016/j.immuni.2015.09.004.

Ketchum C, Miller H, Song W, Upadhyaya A. Ligand Mobility Regulates B Cell Receptor Clustering and Signaling Activation. Biophysical Journal. 2014 jan; 106(1):26–36. http://linkinghub.elsevier.com/retrieve/pii/S0006349513057482, doi: 10.1016/j.bpj.2013.10.043.

Kirk SJ, Cliff JM, Thomas JA, Ward TH. Biogenesis of secretory organelles during B cell differentiation. Journal of Leukocyte Biology. 2010 feb; 87(2):245–255. http://www.ncbi.nlm.nih.gov/pubmed/19889725, doi: 10.1189/jlb.1208774.

Kumari S, Curado S, Mayya V, Dustin ML. T cell antigen receptor activation and actin cytoskeleton remodeling. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2014 feb; 1838(2):546–556. http://linkinghub.elsevier.com/retrieve/pii/S0005273613001508, doi: 10.1016/j.bbamem.2013.05.004.

Kumari S, Depoil D, Martinelli R, Judokusumo E, Carmona G, Gertler FB, Kam LC, Carman CV, Burkhardt JK, Irvine DJ, Dustin ML. Actin foci facilitate activation of the phospholipase C-γ in primary T lymphocytes via the WASP pathway. eLife. 2015 mar; 4:1–31. https://elifesciences.org/articles/04953, doi: 10.7554/eLife.04953.

Kumari S, Vardhana S, Cammer M, Curado S, Santos L, Sheetz MP, Dustin ML. T Lymphocyte Myosin IIA is Required for Maturation of the Immunological Synapse. Frontiers in Immunology. 2012; 3(August):1–13. http://journal.frontiersin.org/article/10.3389/fimmu.2012.00230/abstract, doi: 10.3389/fimmu.2012.00230.

Lin KBL, Freeman SA, Zabetian S, Brugger H, Weber M, Lei V, Dang-Lawson M, Tse KWK, Santamaria R, Batista FD, Gold MR. The Rap GTPases Regulate B Cell Morphology, Immune-Synapse Formation, and Signaling by Particulate B Cell Receptor Ligands. Immunity. 2008 jan; 28(1):75–87. http://linkinghub.elsevier.com/retrieve/pii/S1074761307005845, doi: 10.1016/j.immuni.2007.11.019.

Liu C, Bai X, Wu J, Sharma S, Upadhyaya A, Dahlberg CIM, Westerberg LS, Snapper SB, Zhao X, Song W. N-WASP Is Essential for the Negative Regulation of B Cell Receptor Signaling. PLoS Biology. 2013 nov; 11(11):e1001704. http://dx.plos.org/10.1371/journal.pbio.1001704, doi: 10.1371/journal.pbio.1001704.

Liu C, Miller H, Hui KL, Grooman B, Bolland S, Upadhyaya A, Song W. A Balance of Bruton's Tyrosine Kinase and SHIP Activation Regulates B Cell Receptor Cluster Formation by Controlling Actin Remodeling. The Journal of Immunology. 2011 jul; 187(1):230–239. http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1100157, doi: 10.4049/jimmunol.1100157.

Liu C, Miller H, Orlowski G, Hang H, Upadhyaya A, Song W. Actin Reorganization Is Required for the Formation of Polarized B Cell Receptor Signalosomes in Response to Both Soluble and Membrane-Associated Antigens. The Journal of Immunology. 2012 apr; 188(7):3237–3246. http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1103065, doi: 10.4049/jimmunol.1103065.

Manders EMM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal images. Journal of Microscopy. 1993 mar; 169(3):375–382. http://doi.wiley.com/10.1111/j.1365-2818.1993.tb03313.x, doi: 10.1111/j.1365-2818.1993.tb03313.x.

Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, Carter R, Justement LB, Bruckbauer A, Batista FD. The Actin and Tetraspanin Networks Organize Receptor Nanoclusters to Regulate B Cell Receptor-Mediated Signaling. Immunity. 2013 mar; 38(3):461–474. http://linkinghub.elsevier.com/retrieve/pii/S1074761313000976, doi: 10.1016/j.immuni.2012.11.019.

Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nature Reviews Molecular Cell Biology. 2008 jun; 9(6):446–454. http://www.nature.com/articles/nrm2406, doi: 10.1038/nrm2406.

Michelot A, Drubin DG. Building Distinct Actin Filament Networks in a Common Cytoplasm. Current Biology. 2011 jul; 21(14):R560–R569. http://linkinghub.elsevier.com/retrieve/pii/S0960982211006646, doi: 10.1016/j.cub.2011.06.019.

Mogilner A, Oster G. Cell motility driven by actin polymerization. Biophysical Journal. 1996 dec; 71(6):3030–3045. http://linkinghub.elsevier.com/retrieve/pii/S0006349596794961, doi: 10.1016/S0006-3495(96)79496-1.

Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, Hogquist KA. T cell receptor signal strength in T reg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. The Journal of Experimental Medicine. 2011 jun; 208(6):1279–1289. http://jem.rupress.org/content/208/6/1279, doi: 10.1084/jem.20110308.

Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. BMC bioinformatics. 2006 mar; 7(1):123. http://www.ncbi.nlm.nih.gov/pubmed/16526949, doi: 10.1186/1471-2105-7-123.

Murugesan S, Hong J, Yi J, Li D, Beach JR, Shao L, Meinhardt J, Madison G, Wu X, Betzig E, Hammer JA. Formin-generated actomyosin arcs propel T cell receptor microcluster movement at the immune synapse. The Journal of Cell Biology. 2016 nov; 215(3):383–399. http://www.jcb.org/lookup/doi/10.1083/jcb.201603080, doi: 10.1083/jcb.201603080.

Natkanski E, Lee WY, Mistry B, Casal A, Molloy JE, Tolar P. B Cells Use Mechanical Energy to Discriminate Antigen Affinities. Science. 2013 jun; 340(6140):1587–1590. http://www.sciencemag.org/cgi/doi/10.1126/science.1237572, doi: 10.1126/science.1237572.

Nicholson-Dykstra SM, Higgs HN. Arp2 depletion inhibits sheet-like protrusions but not linear protrusions of fibroblasts and lymphocytes. Cell Motility and the Cytoskeleton. 2008 nov; 65(11):904–922. http://doi.wiley.com/10.1002/cm.20312, doi: 10.1002/cm.20312.

Nowosad CR, Spillane KM, Tolar P. Germinal center B cells recognize antigen through a specialized immune synapse architecture. Nature immunology. 2016 jul; 17(7):870–7. http://www.nature.com/articles/ni.3458, doi: 10.1038/ni.3458.

O'Rourke LM, Tooze R, Turner M, Sandoval DM, Carter RH, Tybulewicz VLJ, Fearon DT. CD19 as a Membrane-Anchored Adaptor Protein of B Lymphocytes: Costimulation of Lipid and Protein Kinases by Recruitment of Vav. Immunity. 1998 may; 8(5):635–645. http://linkinghub.elsevier.com/retrieve/pii/S1074761300805683, doi: 10.1016/S1074-7613(00)80568-3.

Pollard TD. Regulation of Actin Filament Assembly by Arp2/3 Complex and Formins. Annual Review of Biophysics and Biomolecular Structure. 2007 jun; 36(1):451–477. http://www.annualreviews.org/doi/abs/10.1146/annurev.biophys.35.040405.101936, doi: 10.1146/annurev.biophys.35.040405.101936.

Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003 feb; 112(4):453–65. http://www.ncbi.nlm.nih.gov/pubmed/12600310.

Ponti A, Machacek M, Gupton SL, Waterman-Storer CM, Danuser G. Two distinct actin networks drive the protrusion of migrating cells. Science (New York, NY). 2004 sep; 305(5691):1782–6. http://www.sciencemag.org/cgi/doi/10.1126/science.1100533, doi: 10.1126/science.1100533.

Rotty JD, Wu C, Bear JE. New insights into the regulation and cellular functions of the ARP2/3 complex. Nature Reviews Molecular Cell Biology. 2013 jan; 14(1):7–12. http://www.nature.com/articles/nrm3492, doi: 10.1038/nrm3492.

Rowley R, Burkhardt A, Chao H, Matsueda G, Bolen J. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. Journal of Biological Chemistry. 1995 may; 270(19):11590–11594. http://www.jbc.org/lookup/doi/10.1074/jbc.270.19.11590, doi: 10.1074/jbc.270.19.11590.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nature Methods. 2012 jul; 9(7):676–682. http://www.nature.com/articles/nmeth.2019, doi: 10.1038/nmeth.2019.

Schnyder T, Castello A, Feest C, Harwood NE, Oellerich T, Urlaub H, Engelke M, Wienands J, Bruckbauer A, Batista FD. B Cell Receptor-Mediated Antigen Gathering Requires Ubiquitin Ligase Cbl and Adaptors Grb2 and Dok-3 to Recruit Dynein to the Signaling Microcluster. Immunity. 2011 jun; 34(6):905–918. http://linkinghub.elsevier.com/retrieve/pii/S1074761311002305, doi: 10.1016/j.immuni.2011.06.001.

Song W, Liu C, Upadhyaya A. The pivotal position of the actin cytoskeleton in the initiation and regulation of B cell receptor activation. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2014 feb; 1838(2):569–578. http://linkinghub.elsevier.com/retrieve/pii/S0005273613002563, doi: 10.1016/j.bbamem.2013.07.016.

Spillane KM, Tolar P. B cell antigen extraction is regulated by physical properties of antigen-presenting cells. The Journal of Cell Biology. 2017 jan; 216(1):217–230. http://www.jcb.org/lookup/doi/10.1083/jcb.201607064, doi: 10.1083/jcb.201607064.

Suarez C, Kovar DR. Internetwork competition for monomers governs actin cytoskeleton organization. Nature Reviews Molecular Cell Biology. 2016 dec; 17(12):799–810. http://www.nature.com/articles/nrm.2016.106, doi: 10.1038/nrm.2016.106.

Tolar P. Cytoskeletal control of B cell responses to antigens. Nature Reviews Immunology. 2017 jul; 17(10):621–634. http://www.nature.com/doifinder/10.1038/nri.2017.67, doi: 10.1038/nri.2017.67.

Treanor B, Depoil D, Bruckbauer A, Batista FD. Dynamic cortical actin remodeling by ERM proteins controls BCR microcluster organization and integrity. The Journal of Experimental Medicine. 2011 may; 208(5):1055–1068. http://www.jem.org/lookup/doi/10.1084/jem.20101125, doi: 10.1084/jem.20101125.

Treanor B, Depoil D, Gonzalez-Granja A, Barral P, Weber M, Dushek O, Bruckbauer A, Batista FD. The Membrane Skeleton Controls Diffusion Dynamics and Signaling through the B Cell Receptor. Immunity. 2010 feb; 32(2):187–199. http://linkinghub.elsevier.com/retrieve/pii/S1074761310000439, doi: 10.1016/j.immuni.2009.12.005.

Treanor B, Harwood NE, Batista FD. Microsignalosomes: spatially resolved receptor signalling. Biochemical Society Transactions. 2009 oct; 37(5):1014–1018. http://www.biochemsoctrans.org/content/37/5/1014.abstract, doi: 10.1042/BST0371014.

Tuveson D, Carter R, Soltoff S, Fearon D. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science. 1993 may; 260(5110):986–989. http://www.sciencemag.org/cgi/doi/10.1126/science.7684160, doi: 10.1126/science.7684160.

Wan Z, Zhang S, Fan Y, Liu K, Du F, Davey AM, Zhang H, Han W, Xiong C, Liu W. B Cell Activation Is Regulated by the Stiffness Properties of the Substrate Presenting the Antigens. The Journal of Immunology. 2013 may; 190(9):4661–4675. http://www.ncbi.nlm.nih.gov/pubmed/23554309, doi: 10.4049/jimmunol.1202976.

Wan Z, Chen X, Chen H, Ji Q, Chen Y, Wang J, Cao Y, Wang F, Lou J, Tang Z, Liu W. The activation of IgM- or isotype-switched IgG- and IgE-BCR exhibits distinct mechanical force sensitivity and threshold. eLife. 2015 aug; 4(AUGUST2015):1–24. https://elifesciences.org/articles/06925, doi: 10.7554/eLife.06925.

Wang JC, Bolger-Munro M, Gold MR. Imaging the Interactions Between B Cells and Antigen-Presenting Cells. In: *Methods in molecular biology (Clifton, N.J.)*, vol. 1707 Humana Press, New York, NY; 2018.p. 131–161. http://www.ncbi.nlm.nih.gov/pubmed/29388105, doi: 10.1007/978-1-4939-7474-0_10.

Wang JC, Lee JYJ, Christian S, Dang-Lawson M, Pritchard C, Freeman SA, Gold MR. The Rap1–cofilin-1 pathway coordinates actin reorganization and MTOC polarization at the B cell immune synapse. Journal of Cell Science. 2017 feb; 130(6):1094–1109. http://jcs.biologists.org/lookup/doi/10.1242/jcs.191858, doi: 10.1242/jcs.191858.

Weber M, Treanor B, Depoil D, Shinohara H, Harwood NE, Hikida M, Kurosaki T, Batista FD. Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. The Journal of Experimental Medicine. 2008 apr; 205(4):853–868. http://www.jem.org/lookup/doi/10.1084/jem.20072619, doi: 10.1084/jem.20072619.

Westerberg LS, Meelu P, Baptista M, Eston MA, Adamovich DA, Cotta-de Almeida V, Seed B, Rosen MK, Vandenberghe P, Thrasher AJ, Klein C, Alt FW, Snapper SB. Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. The Journal of Experimental Medicine. 2010 jun; 207(6):1145–1152. http://www.jem.org/lookup/doi/10.1084/jem.20091245, doi: 10.1084/jem.20091245.

Wong S, Guo WH, Wang YL. Fibroblasts probe substrate rigidity with filopodia extensions before occupying an area. Proceedings of the National Academy of Sciences. 2014; 111(48):17176–17181. http://www.pnas.org/lookup/doi/10.1073/pnas.1412285111, doi: 10.1073/pnas.1412285111.

Xu L, Li G, Wang J, Fan Y, Wan Z, Zhang S, Shaheen S, Li J, Wang L, Yue C, Zhao Y, Wang F, Brzostowski J, Chen YH, Zheng W, Liu W. Through an ITIM-Independent Mechanism the Fc RIIB Blocks B Cell Activation by Disrupting the Colocalized Microclustering of the B Cell Receptor and CD19. The Journal of Immunology. 2014 jun; 192(11):5179–5191. http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1400101, doi: 10.4049/jimmunol.1400101.

Yang Q, Zhang XF, Pollard TD, Forscher P. Arp2/3 complex–dependent actin networks constrain myosin II function in driving retrograde actin flow. The Journal of Cell Biology. 2012 jun; 197(7):939–956. http://www.jcb.org/lookup/doi/10.1083/jcb.201111052, doi: 10.1083/jcb.201111052.

Yi J, Wu XS, Crites T, Hammer JA. Actin retrograde flow and actomyosin II arc contraction drive receptor cluster dynamics at the immunological synapse in Jurkat T cells. Molecular Biology of the Cell. 2012 mar; 23(5):834–852. http://www.molbiolcell.org/doi/10.1091/mbc.e11-08-0731, doi: 10.1091/mbc.e11-08-0731.

York AG, Chandris P, Nogare DD, Head J, Wawrzusin P, Fischer RS, Chitnis A, Shroff H. Instant super-resolution imaging in live cells and embryos via analog image processing. Nature Methods. 2013 nov; 10(11):1122–1126. http://www.nature.com/articles/nmeth.2687, doi: 10.1038/nmeth.2687.

Yuseff MI, Pierobon P, Reversat A, Lennon-Duménil AM. How B cells capture, process and present antigens: a crucial role for cell polarity. Nature Reviews Immunology. 2013 jul; 13(7):475–486. http://www.nature.com/articles/nri3469, doi: 10.1038/nri3469.

Zhang Y, Shen H, Liu H, Feng H, Liu Y, Zhu X, Liu X. Arp2/3 complex controls T cell homeostasis by maintaining surface TCR levels via regulating TCR+ endosome trafficking. Scientific Reports. 2017 dec; 7(1):8952. http://www.nature.com/articles/s41598-017-08357-4, doi: 10.1038/s41598-017-08357-4.

Movies

Video 1. BCR-Ag microclusters coalesce into a cSMAC at the B cell-APC contact site. A20 D1.3 B cells were added to COS-7 APCs expressing mHEL-GFP (white) and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). See also *Figure 1*B. https://www.dropbox.com/s/p9erdjua35xlcx6/Movie1.mov?dl=0

Video 2. Dynamic actin-based protrusions and BCR-Ag microclusters at the B cell-APC contact site. A20 D1.3 B cells expressing F-Tractin-GFP (green) were added to COS-7 APCs expressing mHEL-HaloTag (red) and the B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also *Figure 1*C. https://www.dropbox.com/s/rup0a2ecls6djwe/Movie2.mov?dl=0

Video 3. Actin dynamics in B cells spreading on immobilized anti-IgG antibodies. A20 B cells expressing F-Tractin-GFP were added to anti-IgG-coated coverslips and the contact site was imaged using a Zeiss Airy Disk microscope. Images taken every 2 s. Video playback is 15 frames per second (30X real speed). See also *Figure 1*F. https://www.dropbox.com/s/6lthefufsiycl0g/Movie3.mov?dl=0

Video 4. BCR-Ag microclusters coalesce into a cSMAC in B cells expressing control siRNA. A20 D1.3 B cells expressing control siRNA were added to COS-7 APCs expressing mHEL-GFP and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in *Figure 2*A. https://www.dropbox.com/s/kfws64o7x2rjyul/Mov4.mov?dl=0

Video 5. Impaired cSMAC formation in B cells expressing Arp3 siRNA. A20 D1.3 B cells expressing Arp3 siRNA were added to COS-7 APCs expressing mHEL-GFP and the B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. The video is played back at 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in *Figure 2*A. https://www.dropbox.com/s/giducz38dr3qbty/Mov5.mov?dl=0

Video 6. BCR-Ag microclusters coalesce into a cSMAC in CK-689-treated B cells. A20 D1.3 B cells were pre-treated with 100 µM CK-689 for 1 hr and then added to COS-7 APCs expressing mHEL-GFP (white). The B cell-APC contact site was imaged using spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in *Figure 2*B. https://www.dropbox.com/s/0worcpxe052761s/Mov6.mov?dl=0

Video 7. Impaired cSMAC formation in CK-666-treated B cells. A20 D1.3 B cells were pre-treated with 100 µM CK-666 for 1 hr and then added to COS-7 APCs expressing mHEL-GFP (white). The B cell-APC contact site was imaged spinning disk microscopy. Images taken every 12 s. Video playback is 10 frames per second (120X real speed). Four representative cells are shown. The first cell in the video is also shown in *Figure 2*B. https://www.dropbox.com/s/o42hs2q55degjin/Mov7.mov?dl=0

Video 8. Peripheral actin dynamics in CK-689-treated B cells plated on immobilized anti-IgG. A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with 100 µM CK-689 and then added to anti-IgG-coated coverslips. The contact site was imaged using TIRF-SIM. Images taken every 1s. Video playback is 10 frames per second (10X real speed). See also *Figure 3*E. https://www.dropbox.com/s/ee8fxwak9vr73qd/Movie8.mov?dl=0

Video 9. Impaired peripheral actin dynamics in CK-666-treated B cells plated on immobilized anti-IgG. A20 B cells expressing F-Tractin-GFP were pre-treated for 1 hr with 100 µM CK-666 and then added to anti-IgG-coated coverslips. The contact site was imaged using TIRF-SIM. Images taken every 1s. Video playback is 10 frames per second (10X real speed). See also *Figure 3*E. https://www.dropbox.com/s/f0bxsyoii0n1vpo/Movie9.mov?dl=0

Video 10. Actin and BCR-Ag microcluster dynamics in CK-689-treated B cells interacting with APCs. A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated for 1 hr with 100 µM CK-689 and then added to COS-7 APCs expressing mHEL-HaloTag (red). The B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also *Figure 4* and *Figure 5*. https://www.dropbox.com/s/mexufyqe2z90qx6/Movie10.mov?dl=0

Video 11. Impaired actin and BCR-Ag microcluster dynamics in CK-666-treated B cells interacting with APCs. A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated for 1 hr with 100 µM CK-666 and then added to COS-7 APCs expressing mHEL-HaloTag (red). The B cell-APC contact site was imaged using ISIM. Images taken every 6.6 s. Video playback is 10 frames per second (66X real speed). See also *Figure 4* and *Figure 5*. https://www.dropbox.com/s/p9ccblu8x5j8uj7/Movie11.mov?dl=0

Figure 1–Figure Supplement 1. Schematic of kymograph analysis. (A) Kymographs are 2-D space-time plots. The vertical axis represents time and the horizontal axis represents distance along a line that is fixed in space. The graph shows the time-dependent evolution of the fluorescence intensities for each pixel along the dotted line. Objects that are static, such as the blue dot in (B), yield vertical lines on the kymograph as their locations on the line (orange dashed lines in (A) and (B)) do not change over time. Mobile objects, such as the red dot in (B), yield lines that deviate from the horizontal, with dx/dt being proportional to the object's velocity. Faster motion is indicated by lines with larger deviation from the vertical.

1246

Figure 2–Figure Supplement 1. siRNA-mediated knockdown of Arp3 in A20 B cells. The cells were transfected with control siRNA or Arp3 siRNA. Cell extracts were analyzed by immunoblotting for the Arp3, Arp2, and p34 components of the Arp 2/3 complex, and for actin. Results from two independent experiments are shown.

1247

Figure 2–Figure Supplement 2. CK-666 treatment does not decrease cell viability. (A) Primary murine B cells were treated with 100 μM CK-689 or CK-666, or left untreated for 1 hr. The cells were then stained with 7-AAD to identify dead cells and analyzed by flow cytometry. The percent of live cells (7-AAD negative) was quantified. Each dot represents an independent experiment. Bars represent the mean and error bars represent the SEM. (B) Primary murine B cells were treated with 100 μM CK-689 or CK-666 for the indicated lengths of time and the percent of live (7-AAD-negative) cells was determined. Representative graph from one of two independent experiments.

A

1248

B

Figure 2–Figure Supplement 3. CK-666 does not alter actin organization or dynamics in the COS-7 APCs. (A) COS-7 cells expressing mHEL-HaloTag (red) were allowed to adhere to fibronectin overnight and then treated with 100 µM of the CK-689 control drug (CK-689) or the CK-666 Arp2/3 complex inhibitor for 30 min. The cells were then stained with phalloidin to visualize F-actin. Scale bar: 5 µm. (B) FRAP analysis of membrane-proximal actin-GFP in COS-7 cells. COS-7 cells were transfected with actin-GFP and allowed to spread on fibronectin. The cells were then treated with 100 µM CK-689 or CK-666 for 30 min. Actin-GFP within the indicated ROI was photobleached and fluorescence recovery was measured at 2 s intervals for 1 min. Representative images are shown (left). Scale bar: 5 µm. Kymograph of actin recovery is shown in the middle panel. Red arrow indicates bleach event. Yellow arrow indicates repolymerization of actin at the cell edge. The recovery of actin-GFP fluorescence after photobleaching is graphed in the right panel (mean ± SEM for >17 cells from 2 experiments). The curves were not significantly different as assessed using the Kolmogorov-Smirnov test.

1249 **Figure 2–Figure Supplement 4.** The Arp2/3 complex is important for the coalescence of BCR-Ag microclusters into a cSMAC. Control siRNA- and Arp3 siRNA-transfected A20 D1.3 B cells (A, C, E, G, I), or CK-689- and CK-666-treated A20 D1.3 B cells (B, D, F, H, J), were added to HEL-GFP-expressing COS-7 APCs and imaged every 12 s for 10-14 min by spinning disk microscopy. (A,B) For each B cell, the total fluorescence intensity of Ag that was gathered into clusters at the B cell-APC contact site was determined for every frame in the video. The data are plotted as mean (line) ± SEM (shaded area) for 9 cells (control siRNA), 12 cells (Arp3 siRNA), 10 cells (CK-689) or 6 cells (CK-666) from a representative experiment. (C,D) For each B cell, the number of Ag clusters formed at the B cell-APC contact site was determined for every frame in the video. The data are plotted as mean ± SEM. (E-F) The distance between each microcluster and the center of mass of Ag fluorescence was calculated for each cell for every frame in the video. For each cell, the average distance from the center of Ag fluorescence for all microclusters was calculated for each time point and normalized to the maximum average distance for that cell. This normalized average distance from the center is plotted as mean ± SEM. (G,H) Kymographs depicting the locations of microclusters along a line extending across the immune synapse. In the control cells, the microclusters depicted move centripetally and then coalesce with other microclusters for form a cSMAC. When the Arp2/3 complex is depleted (G) or inhibited (H), the microclusters are largely static. Cells represented here are the same as those shown in **Figure 2** and are the first cells depicted in **Video 4** (control siRNA), **Video 5** (Arp3 siRNA), **Video 6** (CK-689), and **Video 7** (CK-666). (I,J) The number of Ag clusters per cell required to contain >90% of the total Ag fluorescence intensity after 10 min of contact with the APCs was quantified and is plotted as a cumulative frequency curve. Dots show the 50th percentile (cumulative frequency = 0.5) for the number of clusters per cell required to contain 90% of the Ag fluorescence after 10 min. In (C-I), n= 35 control siRNA-transfected cells and 48 Arp3 siRNA-transfected cells from 4 experiments. In (D-J), n = 18 CK-689-treated cells and 20 CK-666-treated cells from 3 experiments. Mann-Whitney U or Kolmogorov–Smirnov tests were used to calculate p values. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns, not significant. For each cell analyzed, the fraction of the total Ag fluorescence intensity in each cluster is shown in ***Figure 2-Figure Supplement 5***.

1250

Figure 2–Figure Supplement 5. Distribution of total Ag fluorescence intensity in individual clusters. For each B cell analyzed in **Figure 2-Figure Supplement 4**, the stacked bar plots show the fraction of the total Ag fluorescence intensity in individual clusters at 10 min after adding the A20 D1.3 B cells to HEL-GFP-expressing COS-7 APCs. Each bar represents one cell. Each colored segment within a bar represents a single Ag cluster, the size of which is proportional to the fraction of the cell's total Ag fluorescence intensity contained within that cluster. The number at the top of each bar is the total number of distinct Ag clusters present at the 10 min time point. In (A) n= 35 control siRNA-transfected cells and 48 Arp3 siRNA-transfected cells from 4 experiments. In (B), n = 18 CK-689-treated cells and 20 CK-666-treated cells from 3 experiments.

A

B

Figure 3–Figure Supplement 1. Actin and myosin structures in B cells spreading on immobilized anti-IgG. (A) A20 B cells were allowed to spread on anti-IgG-coated coverslips for 15 min before being imaged by STED microscopy. Yellow arrowheads indicate linear actin structures embedded within the peripheral branched actin network. Green arrowheads indicate actin arcs. Scale bars: 10 μm. (B) A20 B cells that had been transfected with myosin IIA-GFP were allowed to spread on anti-IgG-coated coverslips for 10 min. After phalloidin staining, the cells were imaged by spinning disk microscopy. Scale bar: 5 μm.

1252

Figure 4–Figure Supplement 1. Arp2/3 complex activity is required for actin dynamics and for the centripetal movement of BCR-Ag microclusters at the periphery of the B cell-APC contact site. A20 D1.3 B cells expressing F-Tractin-GFP (green) were pre-treated with 100 µM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing mHEL-HaloTag (red). The cells were then imaged every 6.6 s for 6 min using ISIM. Images from movies are shown for representative cells (A). The total area searched by these cells over the 6-minute period of observation is shown (B). Scale bars: 5 µm. The B cell-APC contact area for these cells, as a function of time, is shown in **Figure 4**C (dashed lines). The kymographs (C) represent a time series of images taken along the white dashed lines in (A).

Figure 6–Figure Supplement 1. Arp2/3 complex activity amplifies CD79 phosphorylation. (A) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the single-chain anti-Igκ surrogate Ag. The cells were fixed at the indicated times and stained for the surrogate Ag. For each condition, the total fluorescence intensity of Ag that had been gathered into clusters at the B cell-APC contact site was quantified for >20 cells per experiment. The means ± SEM for the median values from 11 independent experiments are graphed. ns, not significant (p=0.3702, p=0.3573, p=0.3044, p=0.1644, p=0.4388, p=0.6089 for the 1, 3, 5, 10, 15, and 30 min time points, respectively); two-tailed paired t-test. (B) Primary murine B cells were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the anti-Igκ surrogate Ag. The cells were fixed after 3, 5, 10, 15 and 30 min and stained for surrogate Ag (anti-Igκ) and pCD79. For each B cell, the total fluorescence intensity of clustered pCD79 was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. For each condition, the median values for this ratio were determined in each experiment. The graph shows the median values of pCD79/Ag in CK-666-treated B cells as a percent of the median values in CK-689-treated control cells (=100%) for the 5 and 10 min time points from 5 independent experiments. The number of cells analyzed for each condition was >75 (expt 1), >7 (expt 2), >39 (expt 3), >116 (expt 4), and >75 (expt 5), respectively. CK-666/CK-689 ratios were not significantly different from 100% at 15 and 30 min. (C,D) Primary murine B cells from MD4 mice were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the mHEL-HaloTag Ag. The cells were fixed at the indicated times and then stained for pCD79. Images of representative cells are shown (C). Scale bar: 2 μm. For each B cell, the total fluorescence intensity of clustered pCD79 was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. In the beeswarm plots, each dot is one cell. For each time point, the median (red line) and interquartile ranges (red box) for >71 cells from a representative experiment are shown (B). ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns, not significant. Two-tailed paired t-test for panels A and B. Mann-Whitney U test for panel D.

A

APC-bound Ag

1254

B

Soluble anti-Igκ

Figure 6–Figure Supplement 2. Additional independent experiment associated with Figure 6C,D. Primary murine B cells were pre-treated with 100 µM CK-689 or CK-666 for 1 hr and then added to COS-7 APCs expressing the single-chain anti-Igκ surrogate Ag (C) or stimulated with 10 µg/ml soluble anti-Igκ, (B) for the indicated times. pCD79 and total CD79a immunoblots are shown (left panels) and the pCD79/total CD79a ratios are graphed (right panels). The dotted red lines correspond to the pCD79/total CD79a ratio for unstimulated CK-689-treated B cells. Representative data from one of 7 experiments. See ***Figure 9-Figure Supplement 6*** for full blots.

A

B

C

1255

Figure 6–Figure Supplement 3. Arp2/3 complex activity amplifies Syk phosphorylation. (A) Primary murine B cells were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the anti-Igκ surrogate Ag. The cells were fixed after 3, 5, 10, 15 and 30 min and stained for surrogate Ag (anti-Igκ) and pSyk. For each B cell, the total fluorescence intensity of clustered pSyk was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. For each condition, the median values for this ratio were determined for >10 cells per experiment. The graph shows the median values of pSyk/Ag in CK-666-treated B cells as a percent of the median values in CK-689-treated control cells (=100%) from 3 independent experiments at the 3 min time point. CK-666/CK-689 ratios were not significantly different from 100% at 5, 10, 15 and 30 min. (B-C) Primary murine B cells from MD4 mice were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the mHEL-HaloTag Ag. The cells were fixed at the indicated times and then stained for the Ag and pSyk. Images of representative cells are shown (B). Scale bar: 2 µm. For each B cell, the total fluorescence intensity of clustered pSyk was divided by the total fluorescence intensity of clustered Ag at the B cell-APC contact site. Each dot is one cell. The median (red line) and interquartile ranges (box) for >40 cells from a representative experiment are shown (C). ****$p<0.0001$; ***$p<0.001$; **$p<0.01$; *$p<0.05$; ns, not significant. Two-tailed paired t-test for panels A, Mann-Whitney U test for panel C.

1256

Figure 8–Figure Supplement 1. Arp2/3 complex activity increases CD19 phosphorylation in response to membrane-bound Ags. (A) Primary murine B cells were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 cells expressing the anti-Igκ surrogate Ag. The cells were fixed at indicated times and stained for surrogate Ag (anti-Igκ) and pCD19. For each B cell, the total fluorescence intensity of clustered pCD19 was calculated. For each condition, the median pCD19 fluorescence intensity was determined for >15 cells per experiment. For each experiment, the median pCD19 fluorescence intensity for CK-666-treated cells was expressed as a percent of the median value for CK-689-treated cells (=100%). This ratio is plotted for 4 independent experiments. (B) Primary murine B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then stimulated with 10 μg/ml soluble anti-Igκ for the indicated times. pCD19 and total CD79a (loading control) immunoblots are shown (left panels) and the pCD19/total CD79a ratios are graphed (right panels). Dotted red line corresponds to the pCD19/total CD79a ratio value for unstimulated CK-689-treated B cells. Representative data from one of 3 experiments. See ***Figure 9-Figure Supplement 6*** for full blots. (C) The co-localization of pSyk with BCR-Ag clusters is not dependent on Arp2/3 complex activity. The co-localization of pSyk and Ag in the cells that were analyzed in **Figure 6**F was quantified using Manders' coefficient.

A

Gating and Analysis Strategy:

Lymphocytes ➝ Single Cells ➝ GFP+ Cells ➝ Geometric Mean of +ve Cells ➝ [(Ag-APC) - (No-Ag-APC)]

B

1257

Figure 9–Figure Supplement 1. Gating strategy for GFP expression. (A) Schematic of gating strategy. In **Figure 9**B, isolated primary murine B cells from Nur77^{GFP} reporter mice were pre-treated with CK-689 or CK-666 for 1 hr. These cells were then cultured by themselves for 3 hr (No APC) or cultured with either parental COS-7 cells (No-Ag-APC) or COS-7 cells expressing membrane-bound anti-Igκ (Ag-APC) for 3 hr. The cells were then analyzed for GFP expression by flow cytometry. Lymphocytes were gated on using SSC-A and FSC-A. Single cells were gated on using FSC-W and FSC-A. The geometric mean (GM) of the GFP fluorescence was calculated for GFP+-gated cells. To quantify Ag-induced increases in GFP fluorescence, the GM for GFP+ B cells that had been added to parental COS-7 APCs was subtracted from the GM of GFP+ B cells that had been added anti-Igκ-expressing COS-7 APCs. (B,C) Examples of these calculations for CK-689-treated (B) and CK-666-treated (C) B cells are shown. In **Figure 9**B, the Ag-induced increase in the GFP fluorescence for the CK-666-treated cells value is expressed as a percent of the corresponding value for the CK-689-treated cells.

A

Gating and Analysis Strategy:

Lymphocytes → Single Cells → DAPI- Cells → Size [CD69 CD86] → Geometric Mean of +ve Cells → [(Ag-APC) - (No-Ag-APC)]

1258

Figure 9–Figure Supplement 2. Gating strategy for CD69 and CD86 upregulation and blast cell formation. (A) Schematic of gating strategy. In **Figure 9**C-G, primary murine B cells from C57BL/6J mice were either left untreated and cultured by themselves for 18 hr, or were pre-treated for 1 hr with CK-689 or CK-666 and then cultured with either parental COS-7 cells (No-Ag-APC) or COS-7 cells expressing membrane-bound anti-Igκ (Ag-APC) for 18 hr. Lymphocytes were gated on using SSC-A and FSC-A. Single cells were gated on using FSC-W and FSC-A. Dead cells were excluded by DAPI staining. The cells were then analyzed for cell surface expression of CD69 or CD86 by flow cytometry. (B) Representative flow cytometry analysis for B cells that were left untreated and not co-cultured with APCs. (C,D) To quantify Ag-induced increases in the expression of CD69 or CD86, the GM of the CD69+ or CD86+ B cells that had been added to parental COS-7 APCs was subtracted from the GM of CD69+ or CD86+ B cells that had been added anti-Igκ-expressing COS-7 APCs. Examples of these calculations for CK-689-treated (C) and CK-666-treated (D) B cells are shown. In **Figure 9**C-F, the Ag-induced increase in the expression of CD69 or CD86 for the CK-666-treated cells is expressed as a percent of the corresponding value for the CK-689-treated cells. Blast cells were identified as SSC-A^hi and FSC-A^hi cells and the percent of DAPI-negative blast cells is graphed in **Figure 9**G.

1259

Figure 9–Figure Supplement 3. Depletion of the Arp2/3 complex in APCs does not affect B cell activation responses. The APCs used were untransfected B16F1 murine melanoma cells (white in panels C-F) or B16F1 cells transfected with the single chain anti-Igκ alone (grey), anti-Igκ plus control siRNA (blue), or anti-Igκ plus Arp3 siRNA (green). (A) Schematic of experimental work flow. (B) B16F1 cells that had been transfected with control siRNA or Arp3 siRNA were analyzed by immunoblotting for Arp3 and actin. Results from one representative experiment are shown. (C,D) Primary murine B cells were added to the different APC populations for 18 hr. Cell surface levels of CD69 (C) and CD86 (D) were quantified by flow cytometry. The Ag-induced increases in CD69 and CD86 fluorescence were calculated as in **Figure 9**C,D. The data are expressed relative to the increase in CD69 or CD86 expression stimulated by APCs that had been transfected with only the single chain anti-Igκ (the MFI for these cells is indicated by the dotted line on the histogram). Each dot represents an independent experiment and bars represent the median. (E) Primary B cells were pre-treated CK-689 (grey) or CK-666 (orange) for 1 hr and added to untrasfected (No-Ag-APC) B16F1 cells (unfilled curves) or B16F1 cells that had been transfected with single chain anti-Igκ plus Arp3 siRNA (filled curves). The MFI for CK-689-treated cells that were added to Ag-bearing Arp3 siRNA-transfected APCs is indicated by the dotted line. (F) CK-666-treated B cells were added to B16F1 APCs expressing membrane-bound anti-Igκ alone (grey filled bar), anti-Igκ plus control siRNA (blue filled bar), or anti-Igκ plus Arp3 siRNA (green filled bar). Ag-induced increases in CD69 and CD86 expression were calculated as in **Figure 9**C,D. Each dot represents one independent experiment and bars represent the median. Two-tailed paired t-test.

1260

Figure 9–Figure Supplement 4. Washout of CK-666 allows normal APC-induced upregulation of CD69 and cSMAC formation. (A) Primary murine B cells were treated with CK-689 or CK-666 for 1 hr and then added to COS-7 APCs expressing membrane-bound anti-Igκ (Ag-APC) or to parental COS-7 cells (No-Ag-APC). The culture medium was removed at the indicated times after adding the B cells to the APCs and replaced with medium lacking CK-689 or CK-666. For t=0, the drugs were washed out immediately before adding the B cells to the APCs. After 18 hr, the cells were stained and analyzed for cell surface expression of CD69 as in **Figure 9-Figure Supplement 2**. The increase in CD69 expression in CK-666-treated B cells is expressed as a percent of that for cells that were treated with CK-689 in the identical manner. For each point, the average ± range is shown for 2 experiments. Where no error bars are shown, they were smaller than the symbol. (B-D) A20 D1.3 B cells were pre-treated with 100 μM CK-689 or CK-666 for 1 hr and then added to COS-7 APCs expressing mHEL-HaloTag. These 'no washout' cells were fixed after 10 min of B cell-APC contact. Alternatively, B cells were added to the APCs and after 5 min of contact the drug-containing medium was washed out and replaced with fresh medium (Drug washout). After another 5 min, the cells were fixed. Cells were imaged by spinning disk microscopy (C). Representative images are shown. For each cell, the number of clusters required to contain 90% of the Ag fluorescence was calculated and graphed in (D). Each dot represents one cell and the median (red line) and interquartile ranges (black box) are shown for n>25 cells per condition. Representative data from one of 2 independent experiments. The Mann-Whitney U test was used to calculate p values. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. Scale bars: 5 μm.

1261

Figure 9–Figure Supplement 5. Inhibition of myosin does not affect upregulation of B cell activation markers or cSMAC formation. (A,B) Primary murine B cells were pre-treated with DMSO (control), 50 μM pnBB for 30 min or 100 μM CK-666 for 1 hr and then added to COS-7 APCs expressing anti-Igκ for 18 hr. Cell surface levels of CD69 (A) and CD86 (B) were quantified by flow cytometry. The Ag-induced increases in CD69 and CD86 fluorescence were calculated as in **Figure 9**C,D. Graphs show the increase in expression in CK-666-treated and pnBB-treated B cells as a percent of the response in DMSO-treated controls (=100%). Each dot represents an independent experiment. (C-E) A20 D1.3 B cells were pre-treated with DMSO (control) or 50 μM pnBB for 30 min and then added to COS-7 APCs expressing mHEL-HaloTag. The cells were then fixed at the indicated times and imaged by spinning disk microscopy (C). Representative images are shown. For each cell, the number of clusters required to contain >90% of the Ag fluorescence was calculated and graphed in (D). Each dot represents one cell and the median (red line) and interquartile ranges (black box) are shown for n>57 cells per condition. The percent of cells for which >90% of the total Ag fluorescence intensity was contained in 1 or 2 clusters is graphed in (E).

Figure 9–Figure Supplement 6. Images of full blots. Images of blots that were cropped for presentation in **Figure 6**, ***Figure 6-Figure Supplement 2***, **Figure 7** and ***Figure 8-Figure Supplement 1*** are shown. The portions of the blots that were shown in the indicated figures are outlined by a red dashed box. Molecular weight markers are shown in kDa. (A) Full blots for **Figure 6**C and **Figure 6**D. Primary murine B cells were pre-treated with CK-689 (lanes 1-5) or CK-666 (lanes 6-10) for 1 hr then stimulated with COS-7 APCs expressing anti-Igκ (left) or with soluble anti-Igκ (right) for 0, 3, 5, 15 or 30 min. The upper blots were probed with anti-pCD79 antibodies and the lower blots with anti-CD79a antibodies. (B) Full blots for ***Figure 6-Figure Supplement 2***, an additional independent experiment carried out as in (A). (C) Full blots for **Figure 7**A. Primary murine splenic B cells were treated with DMSO (lane 1), CK-689 (lane 2), CK-666 (lane 3) for 1 hr, or stimulated with anti-Igκ antibodies for 5 min (lane 4). The blots were probed with anti-pAkt plus anti-pERK antibodies (upper blot) or with anti-ERK plus anti-Akt antibodies (lower blot). (D) Full blots for ***Figure 8-Figure Supplement 1B***. Primary murine B cells were pre-treated with CK-689 (lanes 1-5) or CK-666 (lanes 6-10) for 1 hr then stimulated with soluble anti-Igκ for 0, 3, 5, 15 or 30 min. The left blot was probed with anti-pCD19 antibodies and the right blot with anti-CD79a antibodies as a loading control.